0001564590-22-007930 | 10-K | XBRL Viewer | Acadia Healthcare Company INC

Print Document View Excel Document

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 133,813	$ 378,697
Accounts receivable, net	281,332	273,551
Other current assets	79,886	61,332
Current assets held for sale		1,809,815
Total current assets	495,031	2,523,395
Property and equipment, net	1,771,159	1,622,896
Goodwill	2,199,937	2,105,264
Intangible assets, net	70,145	68,535
Deferred tax assets	3,080	3,209
Operating lease right-of-use assets	133,761	96,937
Other assets	94,965	79,126
Total assets	4,768,078	6,499,362
Current liabilities:
Current portion of long-term debt	18,594	153,478
Accounts payable	98,575	87,815
Accrued salaries and benefits	137,845	124,912
Current portion of operating lease liabilities	23,348	18,916
Other accrued liabilities	126,499	178,453
Derivative instrument liabilities		84,584
Current liabilities held for sale		660,027
Total current liabilities	404,861	1,308,185
Long-term debt	1,478,626	2,968,948
Deferred tax liabilities	74,368	50,017
Operating lease liabilities	116,841	84,029
Other liabilities	110,505	133,412
Total liabilities	2,185,201	4,544,591
Redeemable noncontrolling interests	65,388	55,315
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 89,028,158 and 88,024,395 issued and outstanding as of December 31, 2021 and 2020, respectively	890	880
Additional paid-in capital	2,636,350	2,580,327
Accumulated other comprehensive loss		(371,365)
Accumulated deficit	(119,751)	(310,386)
Total equity	2,517,489	1,899,456
Total liabilities and equity	$ 4,768,078	$ 6,499,362

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	89,028,158	88,024,395
Common stock, shares outstanding	89,028,158	88,024,395

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 2,314,394	$ 2,089,929	$ 2,008,381
Salaries, wages and benefits (including equity-based compensation expense of $37,530, $22,504 and $17,307, respectively)	1,243,804	1,154,522	1,107,357
Professional fees	136,739	120,489	118,451
Supplies	90,702	87,241	85,534
Rents and leases	38,519	37,362	35,486
Other operating expenses	301,339	262,272	259,536
Income from provider relief fund	(17,900)	(32,819)
Depreciation and amortization	106,717	95,256	87,923
Interest expense, net	76,993	158,105	187,325
Debt extinguishment costs	24,650	7,233
Loss on impairment	24,293	4,751	27,217
Transaction-related expenses	12,778	11,720	21,157
Total expenses	2,038,634	1,906,132	1,929,986
Income from continuing operations before income taxes	275,760	183,797	78,395
Provision for income taxes	67,557	40,606	25,085
Income from continuing operations	208,203	143,191	53,310
(Loss) income from discontinued operations, net of taxes	(12,641)	(812,390)	56,812
Net income (loss)	195,562	(669,199)	110,122
Net income attributable to noncontrolling interests	(4,927)	(2,933)	(1,199)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 190,635	$ (672,132)	$ 108,923
Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 2.29	$ 1.60	$ 0.59
(Loss) income from discontinued operations	(0.14)	(9.25)	0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	2.15	(7.65)	1.24
Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	2.24	1.58	0.59
(Loss) income from discontinued operations	(0.14)	(9.17)	0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 2.10	$ (7.59)	$ 1.24
Weighted-average shares outstanding:
Basic	88,769	87,875	87,612
Diluted	90,793	88,595	87,816

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Equity-based compensation expense	$ 37,530	$ 22,504	$ 17,307

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 195,562	$ (669,199)	$ 110,122
Other comprehensive income (loss):
Foreign currency translation (loss) gain	(4,260)	61,247	69,811
Gain (loss) on derivative instruments, net of tax of $0.1 million, $(3.9) million and $(3.6) million, respectively	19	(11,272)	(19,008)
Pension liability adjustment, net of tax of $0.0 million, $(0.8) million and $(0.6) million, respectively		(6,456)	(3,310)
U.K. Sale	375,606
Other comprehensive income	371,365	43,519	47,493
Comprehensive income (loss)	566,927	(625,680)	157,615
Comprehensive (income) loss attributable to noncontrolling interests	(4,927)	(2,933)	(1,199)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$ 562,000	$ (628,613)	$ 156,416

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Gain (loss) on derivative instruments, tax	$ 0.1	$ (3.9)	$ (3.6)
Pension liability adjustment, tax	$ 0.0	$ (0.8)	$ (0.6)

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	(Accumulated Deficit) Retained Earnings [Member]
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	$ 2,541,987	$ (462,377)	$ 252,823
Balance, shares at Dec. 31, 2018		87,444,000
Common stock issued under stock incentive plans	$ 569	$ 3	566
Common stock issued under stock incentive plans, shares	55,671	271,000
Common stock withheld for minimum statutory taxes	$ (2,218)		(2,218)
Equity-based compensation expense	17,307		17,307
Other comprehensive income	47,493			47,493
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	108,923				108,923
Balance at Dec. 31, 2019	2,505,381	$ 877	2,557,642	(414,884)	361,746
Balance, shares at Dec. 31, 2019		87,715,000
Common stock issued under stock incentive plans	$ 2,027	$ 3	2,024
Common stock issued under stock incentive plans, shares	68,700	309,000
Common stock withheld for minimum statutory taxes	$ (1,843)		(1,843)
Equity-based compensation expense	22,504		22,504
Other comprehensive income	43,519			43,519
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	(672,132)				(672,132)
Balance at Dec. 31, 2020	$ 1,899,456	$ 880	2,580,327	(371,365)	(310,386)
Balance, shares at Dec. 31, 2020	88,024,395	88,024,000
Common stock issued under stock incentive plans	$ 22,029	$ 10	22,019
Common stock issued under stock incentive plans, shares	558,322	1,004,000
Common stock withheld for minimum statutory taxes	$ (5,734)		(5,734)
Equity-based compensation expense	37,530		37,530
Other comprehensive income	371,365			$ 371,365
Other	2,208		2,208
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	190,635				190,635
Balance at Dec. 31, 2021	$ 2,517,489	$ 890	$ 2,636,350		$ (119,751)
Balance, shares at Dec. 31, 2021	89,028,158	89,028,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net income (loss)	$ 195,562	$ (669,199)	$ 110,122
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities:
Depreciation and amortization	106,717	95,256	87,923
Amortization of debt issuance costs	4,071	12,636	11,987
Equity-based compensation expense	37,530	22,504	17,307
Deferred income taxes	11,772	53,108	1,089
Loss (income) from discontinued operations, net of taxes	12,641	812,390	(56,812)
Debt extinguishment costs	24,650	7,233
Loss on impairment	24,293	4,751	27,217
Other	491	1,041	3,916
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	2,448	15,340	(18,714)
Other current assets	1,968	9,675	(501)
Other assets	(10,770)	1,519	(2,372)
Accounts payable and other accrued liabilities	6,164	41,910	(20,135)
Accrued salaries and benefits	9,755	(10,001)	5,540
Other liabilities	(14,940)	18,082	16,862
Government relief funds	(38,128)	86,599
Net cash provided by continuing operating activities	374,224	502,844	183,429
Net cash provided by discontinued operating activities	253	155,963	149,475
Net cash provided by operating activities	374,477	658,807	332,904
Investing activities:
Cash paid for acquisitions, net of cash acquired	(139,015)		(44,900)
Cash paid for capital expenditures	(244,811)	(224,964)	(232,679)
Proceeds from U.K. Sale	1,511,020
Settlement of foreign currency derivatives	(84,795)		105,008
Proceeds from sale of property and equipment	3,493	92	11,765
Cash paid for purchase of finance lease	(31,401)
Other	3,142	(13,365)	12,975
Net cash provided by (used in) continuing investing activities	1,017,633	(238,237)	(147,831)
Net cash used in discontinued investing activities		(43,602)	(53,310)
Net cash provided by (used in) investing activities	1,017,633	(281,839)	(201,141)
Financing activities:
Borrowings on long-term debt	425,000	925,000
Borrowings on revolving credit facility	500,000	100,000	76,573
Principal payments on revolving credit facility	(330,000)	(100,000)	(76,573)
Principal payments on long-term debt	(7,969)	(41,291)	(52,984)
Repayment of long-term debt	(2,227,935)	(909,785)
Payment of debt issuance costs	(7,964)	(18,295)
Common stock withheld for minimum statutory taxes, net	16,295	184	(1,648)
Distributions to noncontrolling interests	(1,588)	(916)	(154)
Other	(6,900)	(3,146)	(4,369)
Net cash used in continuing financing activities	(1,641,061)	(48,249)	(59,155)
Net cash used in discontinued financing activities		(3,250)	(2,472)
Net cash used in financing activities	(1,641,061)	(51,499)	(61,627)
Effect of exchange rate changes on cash	4,067	4,087	3,546
Net (decrease) increase in cash and cash equivalents, including cash classified within current assets held for sale	(244,884)	329,556	73,682
Less: cash classified within current assets held for sale		(75,051)	(24,657)
Net (decrease) increase in cash and cash equivalents	(244,884)	254,505	49,025
Cash and cash equivalents at beginning of the period	378,697	124,192	50,510
Cash and cash equivalents at end of the period	133,813	378,697	99,535
Supplemental Cash Flow Information:
Cash paid for interest	93,669	137,578	173,239
Cash paid (received) for income taxes	79,304	(16,486)	31,915
Effect of acquisitions:
Assets acquired, excluding cash	176,365	20,200	48,594
Liabilities assumed	(37,350)	(53)	(3,694)
Redeemable noncontrolling interest resulting from an acquisition		$ (20,147)
Cash paid for acquisitions, net of cash acquired	$ 139,015		$ 44,900

Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (the “U.S.”) and Puerto Rico. At December 31, 2021, the Company operated 238 behavioral healthcare facilities with approximately 10,500 beds in 40 states and Puerto Rico.

On January 19, 2021, the Company completed the sale of its operations in the United Kingdom (the “U.K.”) to RemedcoUK Limited, a company organized under the laws of England and Wales and owned by funds managed or advised by Waterland Private Equity Fund VII (the “U.K. Sale”). The U.K. Sale allowed the Company to reduce its indebtedness and focus on its U.S. operations. As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. See Note 3 – U.K. Sale.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as general and administrative expenses include the Company’s corporate office costs, which were $108.2 million, $97.8 million and $90.4 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.

Insurance

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary. The Company is self-insured for professional liability claims up to $3 million per claim through August 31, 2021 and $10.0 million thereafter, and has obtained reinsurance coverage from a third party to cover claims in excess of the retention limit. The reinsurance policy has a coverage limit of $60.0 million in the aggregate beginning September 1, 2021. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place. The reserve for professional and general liability risks was estimated based on historical claims, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The professional and general liability reserve was $87.8 million at December 31, 2021, of which $11.9 million was included in other accrued liabilities and $75.9 million was included in other long-term liabilities. The professional and general liability reserve was $77.5 million at December 31, 2020, of which $9.7 million was included in other accrued liabilities and $67.8 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was $37.9 million at

December 31, 2021, of which $10.8 million was included in other current assets and $27.1 million was included in other assets, and such receivable was $27.2 million at December 31, 2020, of which $6.8 million was included in other current assets and $20.4 million was included in other assets.

The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $23.6 million at December 31, 2021, of which $12.0 million was included in accrued salaries and benefits and $11.6 million was included in other long-term liabilities, and such liability was $23.0 million at December 31, 2020, of which $12.0 million was included in accrued salaries and benefits and $11.0 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $106.7 million, $95.3 million and $87.9 million for the years ended December 31, 2021, 2020 and 2019, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful life, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows. During the second quarter of 2021, the Company opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, the Company recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

The Company performed an impairment review of long-lived assets in the fourth quarter of 2021 and recorded no impairment. The impairment review of long-lived assets in the fourth quarters of 2020 and 2019, indicated the carrying amounts of certain of the Company’s long-lived assets in facilities in the U.S. (the “U.S. Facilities”) may not be recoverable. This created a non-cash impairment of $4.2 million and $27.2 million for the years ended December 31, 2020 and 2019, respectively. These items were recorded in loss on impairment on the Company’s consolidated statements of operations.

Goodwill and Indefinite-Lived Intangible Assets

The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate the carrying value of a reporting unit may not be recoverable.

Subsequent to the U.K. Sale, as of the Company’s annual impairment test on October 1, 2021, the Company had one reporting unit, behavioral health services. The fair value of our behavioral health services reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded. Additionally, during the second quarter of 2021, the Company sold one outpatient facility for $4.3 million and recorded a write down of $1.8 million of goodwill and $0.2 million of intangible assets related to the disposition. During the fourth quarter of 2021, the Company sold one outpatient facility for $1.5 million and recorded a write down of $0.7 million of goodwill and $0.1 million of intangibles related to the disposition.

As of the Company’s annual impairment test on October 1, 2020, the Company had two operating segments for segment reporting purposes, U.S. Facilities and facilities in the U.K. (the “U.K. Facilities”), each of which represented a reporting unit for purposes of the Company’s goodwill impairment test.

The Company’s annual goodwill impairment and other indefinite-lived intangible assets test performed as of October 1, 2020 considered recent financial performance, including the impacts of COVID-19 on certain portions of the U.K. business. The 2020 impairment test of the U.K. Facilities indicated carrying value of the reporting unit exceeded the estimated fair value and resulted in a non-cash loss on impairment of the remaining goodwill of the U.K. Facilities of $356.2 million. The non-cash loss on impairment is included in loss on sale within discontinued operations in the consolidated statements of operations. As of the Company’s impairment test on October 1, 2020, the fair value of the U.S. Facilities reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded. Additionally, for the year ended December 31, 2020, the Company recorded a non-cash impairment charge of $0.6 million related to indefinite-lived assets related to closed facilities in the U.S., which is included in loss on impairment in the consolidated statements of operations.

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2021		2020
Prepaid expenses	$	22,292	$	19,480
Assets held for sale		15,808		—
Workers’ compensation deposits – current portion		12,000		12,000
Insurance receivable – current portion		10,807		6,792
Other receivables		10,786		10,025
Inventory		4,786		4,851
Income taxes receivable		1,523		897
Cost report receivable		—		5,818
Other		1,884		1,469
Other current assets	$	79,886	$	61,332

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2021		2020
Unearned income	$	30,371	$	35,946
Accrued expenses		26,791		28,452
Accrued interest		17,418		40,479
Government relief funds		12,718		5,495
Insurance liability – current portion		11,923		9,700
Accrued property taxes		8,375		6,763
Cost report payable		6,487		—
Income taxes payable		5,540		16,345
Finance lease liabilities		990		32,188
Other		5,886		3,085
Other accrued liabilities	$	126,499	$	178,453

Stock Compensation

The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 718, “ Compensation—Stock Compensation .” The Company uses the Black-Scholes valuation model to determine grant-date fair value for stock options and recognizes straight-line amortization of share-based compensation expense over the requisite service period of the respective awards. The fair values of restricted stock units are determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at their Monte-Carlo simulation value for units subject to market conditions.

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options and non-vested shares, to the extent such securities have a dilutive effect on earnings per share.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

The Company has accruals for taxes and associated interest that may become payable in future years as a result of audits by tax authorities. The Company accrues for tax contingencies when it is more likely than not that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated. Although Management believes that the positions taken on previously filed tax returns are reasonable, the Company nevertheless have established tax and interest reserves in recognition that various taxing authorities may challenge the positions taken by the Company resulting in additional liabilities for taxes and interest. These amounts are reviewed as circumstances warrant and adjusted as events occur that affect the Company’s potential liability for additional taxes, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue.

Recent Accounting Pronouncements

In November 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-10, “Government Assistance (Topic 832)” (“ASU 2021-10”). ASU 2021-10 provides guidance to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. ASU 2021-10 applies to all business entities except for not-for-profit entities within the scope of Topic 958, Not-for-Profit Entities, and employee benefit plans within the scope of Topic 960, Plan Accounting— Defined Benefit Pension Plans, Topic 962, Plan Accounting—Defined Contribution Pension Plans, and Topic 965, Plan Accounting—Health and Welfare Benefit Plans that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance (for example, a grant model within IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or Subtopic 958-605, Not-For-Profit Entities—Revenue Recognition). ASU 2021-10 is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2021-10 on the Company’s consolidated financial statements.

In March 2020, the SEC adopted final rules that amend Rule 3-10 and Rule 3-16 of Regulation S-X to reduce and simplify the financial disclosure requirements applicable to guarantors and issuers of guaranteed securities, as well as for affiliates whose securities collateralize a registrant’s securities. The new rules are effective January 4, 2021. Early adoption is permitted. The Company early adopted the new rules during the second quarter of 2020.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective as of March 12, 2020 through December 31, 2022. Entities may adopt ASU 2020-04 as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. Management is evaluating the impact of ASU 2020-04 on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-402 to determine which implementation costs to capitalize as assets. ASU 2018-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2018-15 on January 1, 2020. There is no significant impact on the Company’s consolidated financial statements.

In August 2017, FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”). ASU 2017-12 amends the hedge accounting model to enable entities to better portray the economics of their risk management activities in the financial statements and simplifies the application of hedge accounting in certain situations. ASU 2017-12 is effective for fiscal years, and interim periods within those years, beginning after December 15,

2018. Early adoption is permitted. The Company adopted ASU 2017-12 on January 1, 2019. There is no significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 replaces the current incurred loss impairment methodology with a new methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2016-13 on January 1, 2020. There is no significant impact on the Company’s consolidated financial statements.

U.K. Sale

12 Months Ended

Dec. 31, 2021

Discontinued Operations And Disposal Groups [Abstract]

U.K. Sale

3. U.K. Sale

On January 19, 2021, the Company completed the U.K. Sale pursuant to a Share Purchase Agreement in which it sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of the Company’s U.K. operations. The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current British Pounds (“GBP”) to U.S. Dollars (“USD”) exchange rate, cash retained by the buyer and transaction costs. The Company used the net proceeds of approximately $1,425 million (excluding cash retained by the buyer) along with cash on the balance sheet to reduce debt by $1,640 million during the first quarter of 2021 as described in Note 11 – Long-Term Debt.

As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. In December 2020, the Company’s U.K. operations met the criteria to be classified as assets held for sale. The carrying value of the U.K. operations was written down to fair value less costs to sell in the consolidated balance sheet at December 31, 2020. This resulted in a loss on sale of $867.3 million, which includes approximately $356.2 million of non-cash goodwill impairment, recorded within discontinued operations in the consolidated statement of operations. During the first quarter of 2021, an additional $14.3 million was recorded as a loss on sale primarily resulting from an increase in the U.K. operations carrying value.

For the years ended December 31, 2021, 2020 and 2019, results of operations of the U.K. operations were as follows (in thousands):

	Year Ended December 31,
	2021			2020			2019
Revenue	$	62,520		$	1,119,768		$	1,099,081
Salaries, wages and benefits		35,937			632,134			609,823
Professional fees		6,815			127,291			122,532
Supplies		2,217			38,285			37,527
Rents and leases		2,509			47,748			46,743
Other operating expenses		6,682			113,534			115,897
Depreciation and amortization		—			74,935			76,121
Interest expense, net		10			(417	)		(231	)
Loss on sale		13,490			867,324			—
Loss on impairment		—			20,239			27,169
Transaction-related expenses		6,265			8,719			5,907
Total expenses		73,925			1,929,792			1,041,488
(Loss) income from discontinued operations before income taxes		(11,405	)		(810,024	)		57,593
Provision for income taxes		1,236			2,366			781
(Loss) income from discontinued operations	$	(12,641	)	$	(812,390	)	$	56,812

The major classes of assets and liabilities for the U.K. operations as of December 31, 2020 are shown below (in thousands):

Cash and cash equivalents	$	75,051
Accounts receivable, net		52,196
Other current assets		13,361
Current assets of discontinued operations		140,608
Property and equipment, net		1,297,923
Goodwill		—
Intangible assets, net		22,289
Operating lease right-of-use assets		341,289
Other assets		7,706
Total assets of discontinued operations		1,809,815

Current liabilities:
Accounts payable	$	44,929
Current portion of operating lease liabilities		11,141
Other current liabilities		136,895
Current liabilities of discontinued operations		192,965
Operating lease liabilities		387,607
Deferred tax liabilities		57,230
Other liabilities		22,225
Total liabilities of discontinued operations	$	660,027

The consolidated cash flows for the years ended December 31, 2020 and 2019 related to the discontinued U.K. operations includes cash paid for capital expenditures of $48.4 million and $59.6 million, respectively.

Revenue

12 Months Ended

Dec. 31, 2021

Revenue From Contract With Customer [Abstract]

Revenue

4. Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms.

As the Company’s performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as the Company’s patients typically are under no obligation to remain admitted in the Company’s facilities.

At December 31, 2021 and 2020, estimated implicit price concessions of $49.7 million and $62.1 million, respectively, had been recorded as reductions to the Company’s accounts receivable balances to enable the Company to record its revenues and accounts receivable at the estimated amounts the Company expected to collect. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated statements of operations.

The Company disaggregates revenue from contracts with customers by service type and by payor.

The Company’s facilities and services provided by the facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; and residential treatment centers.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

The table below presents total U.S. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2021		2020		2019
Acute inpatient psychiatric facilities	$	1,126,872	$	984,609	$	912,097
Specialty treatment facilities		896,564		802,022		788,232
Residential treatment centers		283,169		281,158		286,959
Other		7,789		22,140		21,093
Revenue	$	2,314,394	$	2,089,929	$	2,008,381

The Company receives payments from the following sources for services rendered in its facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of the Company’s facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the consolidated statements of operations. Bad debt expense for the years ended December 31, 2021, 2020 and 2019 was not significant.

The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be estimated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report payables were $6.5 million for the year ended December 31, 2021 and were included in other current liabilities on the consolidated balance sheet. The Company’s cost report receivables were $5.8 million for the year ended December 31, 2020 and were included in other current assets in the consolidated balance sheet. Management believes that these payables or receivables are properly stated and are not likely to be settled for a significantly different amount. The net adjustments to estimated cost report settlements resulted in decreases to revenue of $5.4 million, $1.3 million and $0.4 million for the years ended December 31, 2021, 2020 and 2019, respectively.

The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. Such amounts determined to qualify as charity care are not reported as revenue. The cost of providing charity care services were $3.8 million, $4.4 million and $4.3 million for the years ended December 31, 2021, 2020 and 2019, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from the Company’s most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.

The following table presents revenue by payor type and as a percentage of revenue in the Company’s U.S. Facilities for the years ended December 31, 2021, 2020 and 2019 (in thousands):

	Year Ended December 31,
	2021					2020					2019
	Amount		%			Amount		%			Amount		%
Commercial	$	684,292		29.6	%	$	596,698		28.5	%	$	565,350		28.2	%
Medicare		364,598		15.8	%		330,070		15.8	%		294,691		14.7	%
Medicaid		1,147,884		49.6	%		1,037,852		49.7	%		1,007,102		50.1	%
Self-Pay		93,425		4.0	%		98,302		4.7	%		118,716		5.9	%
Other		24,195		1.0	%		27,007		1.3	%		22,522		1.1	%
Revenue	$	2,314,394		100.0	%	$	2,089,929		100.0	%	$	2,008,381		100.0	%

Contract liabilities primarily consisted of unearned revenue from CMS’ Accelerated and Advance Payment Program. In April 2020, the Company received approximately $45 million from CMS’ Accelerated and Advance Payment Program for Medicare providers. The Company repaid approximately $25 million of the $45 million of advance payments during 2021 via recoupment from the Company’s new Medicare claims and will continue to repay the remaining balance throughout 2022. Contract liabilities of $30.4 million are included in other accrued liabilities at December 31, 2021 on the consolidated balance sheet. Contract liabilities of $35.9 million and $11.3 million are included in other accrued liabilities and other liabilities, respectively, at December 31, 2020 on the consolidated balance sheet. A summary of the activity in contract liabilities is as follows (in thousands):

Balance at December 31, 2020	$	47,196
Payments received		11,739
Revenue recognized		(3,463	)
Medicare advance repayments		(25,101	)
Balance at December 31, 2021	$	30,371

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Earnings Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Earnings Per Share

5. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2021, 2020 and 2019 (in thousands, except per share amounts):

	Year Ended December 31,
	2021			2020			2019
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	203,276		$	140,258		$	52,111
(Loss) income from discontinued operations		(12,641	)		(812,390	)		56,812
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	190,635		$	(672,132	)	$	108,923
Denominator:
Weighted average shares outstanding for basic earnings per share		88,769			87,875			87,612
Effects of dilutive instruments		2,024			720			204
Shares used in computing diluted earnings per common share		90,793			88,595			87,816

Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	2.29		$	1.60		$	0.59
(Loss) income from discontinued operations		(0.14	)		(9.25	)		0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	2.15		$	(7.65	)	$	1.24

Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	2.24		$	1.58		$	0.59
(Loss) income from discontinued operations		(0.14	)		(9.17	)		0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	2.10		$	(7.59	)	$	1.24

Approximately 0.3 million, 1.9 million and 2.2 million shares of common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2021, 2020 and 2019, respectively, because their effect would have been anti-dilutive.

Acquisitions

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Acquisitions

6. Acquisitions

The Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On December 31, 2021, the Company acquired the equity of CenterPointe Behavioral Health System, LLC and certain related entities (“CenterPointe”) for cash consideration of approximately $139 million. The acquisition was funded through a combination of cash on hand and a $70.0 million draw on the Revolving Facility. CenterPointe operates four acute inpatient hospitals with 306 beds and ten outpatient locations primarily in Missouri.

The preliminary fair values of assets acquired and liabilities assumed in the CenterPointe acquisition were as follows (in thousands):

Cash	$	5,640
Accounts receivable, net		10,230
Other current assets		2,087
Property and equipment		35,670
Goodwill		97,122
Intangible assets		825
Deferred tax assets		1,573
Operating lease right-of-use assets		28,858
Total assets acquired		182,005
Accounts payable		3,820
Accrued salaries and benefits		3,585
Current portion of operating lease liabilities		2,582
Other accrued liabilities		1,088
Operating lease liabilities		26,275
Total liabilities assumed		37,350
Net assets acquired	$	144,655

The fair values assigned to certain assets acquired and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. Specifically, the Company is further assessing the valuation of intangible assets and certain tax matters as well as certain receivables and assumed liabilities of CenterPointe. The qualitative factors comprising the goodwill acquired in the CenterPointe acquisition include the value of the business and efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance and applying best practices.

On April 1, 2019, the Company completed the acquisition of Bradford Recovery Center, a specialty treatment facility with 46 beds located in Millerton, Pennsylvania, for cash consideration of approximately $4.5 million.

On February 15, 2019, the Company completed the acquisition of Whittier Pavilion, an inpatient psychiatric facility with 71 beds located in Haverhill, Massachusetts, for cash consideration of approximately $17.9 million. Also on February 15, 2019, the Company completed the acquisition of Mission Treatment for cash consideration of approximately $22.5 million and a working capital settlement. Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona and Oklahoma.

Goodwill

The following table summarizes changes in goodwill for the years 2020 and 2021 (in thousands):

Balance at January 1, 2020	$	2,085,104
Increase from contribution of redeemable noncontrolling interests		20,200
Adjustments related to 2019 acquisitions		(40	)
Balance at December 31, 2020		2,105,264
Increase from acquisitions		97,122
2021 dispositions		(2,449	)
Balance at December 31, 2021	$	2,199,937

Transaction-related expenses

Transaction-related expenses represent costs primarily related to termination, restructuring, strategic review, management transition and other acquisition-related costs. Transaction-related expenses comprised the following costs for the years ended December 31, 2021, 2020 and 2019 (in thousands):

	Year Ended December 31,
	2021		2020		2019
Legal, accounting and other acquisition-related costs	$	8,315	$	8,252	$	3,030
Termination, restructuring and strategic review costs		4,463		3,468		12,598
Management transition costs		—		—		5,529
	$	12,778	$	11,720	$	21,157

Property and Equipment

12 Months Ended

Dec. 31, 2021

Property Plant And Equipment [Abstract]

Property and Equipment

7. Property and Equipment

Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands):

	December 31,
	2021			2020
Land	$	154,376		$	144,221
Building and improvements		1,683,560			1,490,149
Equipment		253,100			220,690
Construction in progress		221,249			217,479
		2,312,285			2,072,539
Less: accumulated depreciation		(541,126	)		(449,643	)
Property and equipment, net	$	1,771,159		$	1,622,896

During the years ended December 31, 2021 and 2020, the Company recorded non-cash impairment charges of $24.3 million and $4.2 million, respectively, related primarily to the closure of certain facilities. During the second quarter of 2021, the Company opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter 2021, the Company recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage. The non-cash impairment charges of $4.2 million for the year ended December 31, 2020 related to the closure of certain facilities.

The Company has recorded assets held for sale within other current assets on the consolidated balance sheets for closed U.S. properties actively marketed of $15.8 million and $17.1 million at December 31, 2021 and 2020, respectively.

Other Intangible Assets

12 Months Ended

Dec. 31, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Other Intangible Assets

8. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2021 and 2020 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2021		December 31, 2020		December 31, 2021			December 31, 2020
Intangible assets subject to amortization:
Non-compete agreements	$	1,131	$	1,131	$	(1,131	)	$	(1,131	)

Intangible assets not subject to amortization:
Licenses and accreditations		11,600		11,873		—			—
Trade names		40,435		39,526		—			—
Certificates of need		18,110		17,136		—			—
		70,145		68,535		—			—
Total	$	71,276	$	69,666	$	(1,131	)	$	(1,131	)

All the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

During the second quarter of 2021, the Company sold one outpatient facility for $4.3 million and recorded a write down of $1.8 million of goodwill and $0.2 million of intangible assets related to the disposition. During the fourth quarter of 2021, the Company sold one outpatient facility for $1.5 million and recorded a write down of $0.7 million of goodwill and $0.1 million of intangibles related to the disposition. These dispositions are reflected in other investing activities in the consolidated statement of cash flows. For the year ended December 31, 2020, the Company recorded a non-cash impairment charge of $0.6 million related to indefinite-lived assets related to closed facilities in the U.S., which is included in loss on impairment in the consolidated statements of operations.

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Leases

9. Leases

The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations.

The Company also elected the accounting policy practical expedients by class of underlying asset in ASC 842 “Leases” to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as right-of-use assets and liabilities on the consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components.

Operating lease liabilities are recorded at the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore, incremental borrowing rates were calculated based on information available at the lease commencement date. The Company reviews service agreements for embedded leases and records right-of-use assets and liabilities as necessary.

Lease Position

The Company recorded the following at December 31, 2021 and 2020 on the consolidated balance sheets (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2021		December 31, 2020
Finance lease right-of-use assets	Property and equipment, net	$	8,627	$	34,621
Operating lease right-of-use assets	Operating lease right-of-use assets		133,761		96,937
Total		$	142,388	$	131,558

Lease Liabilities	Balance Sheet Classification	December 31, 2021		December 31, 2020
Current:
Finance lease liabilities	Other accrued liabilities	$	990	$	32,188
Operating lease liabilities	Current portion of operating lease liabilities		23,348		18,916
Noncurrent:
Finance lease liabilities	Other liabilities		10,807		10,744
Operating lease liabilities	Operating lease liabilities		116,841		84,029
Total		$	151,986	$	145,877

Weighted-average remaining lease terms and discount rates were as follows at December 31, 2021 and 2020:

	December 31,
	2021			2020
Weighted-average remaining lease term (in years):
Finance	22.9			6.7
Operating	9.1			8.5

Weighted-average discount rate:
Finance		5.1	%		5.9	%
Operating		5.1	%		6.5	%

Lease Costs

The Company recorded the following lease costs at December 31, 2021 and 2020 (in thousands):

	December 31,
	2021		2020
Finance lease costs:
Depreciation of leased assets		378		868
Interest of lease liabilities		2,174		3,214
Total finance lease costs	$	2,552	$	4,082

Operating lease costs		28,233		27,050
Variable lease costs		2,488		2,501
Short term lease costs		3,257		3,558
Other lease costs		4,541		4,253
Total rents and leases	$	38,519	$	37,362

Total lease costs	$	41,071	$	41,444

Other

Undiscounted cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2021 (in thousands):

	Finance Leases		Operating Leases
2021	$	990	$	29,973
2022		990		26,471
2023		1,007		23,110
2024		1,089		19,730
2025		1,089		14,500
Thereafter		22,911		68,427
Total minimum lease payments		28,076		182,211
Less: amount of lease payments representing interest		16,279		42,022
Present value of future minimum lease payments		11,797		140,189
Less: Current portion of lease liabilities		990		23,348
Noncurrent lease liabilities	$	10,807	$	116,841

Supplemental data for the years ended December 31, 2021 and 2020 were as follows (in thousands):

	December 31,
	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	27,508	$	26,810
Operating cash flows for finance leases	$	2,174	$	3,214
Financing cash flows for finance leases	$	31,136	$	551

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	63,279	$	21,285
Finance leases	$	—	$	—

The CARES Act

12 Months Ended

Dec. 31, 2021

Extraordinary And Unusual Items [Abstract]

The CARES Act

10. The CARES Act

As part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the U.S. government announced it would offer $100 billion of relief to eligible healthcare providers. On April 24, 2020, then President Trump signed into law the Paycheck Protection Program and Health Care Enhancement Act (the “PPP Act”). Among other things, the PPP Act allocates $75 billion to eligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the PPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. During the three months ended June 30, 2020, the Company participated in certain relief programs offered through the CARES Act, including receipt of approximately $19.7 million relating to the initial portions of the Public Health and Social Services Emergency Fund (“PHSSE Fund”), also known as the Provider Relief Fund, and approximately $45 million of payments from the Centers for Medicare and Medicaid Services’ (“CMS”) Accelerated and Advance Payment Program. In August 2020, the Company received approximately $12.8 million of additional funds from the PHSSE Fund. The Company repaid approximately $25 million of the $45 million of advance payments during 2021 via recoupment from the Company’s new Medicare claims and will continue to repay the remaining balance throughout 2022. In addition, the Company received a 2% increase in facilities’ Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020, to December 31, 2021. In April 2021, the Company received $24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, the Company recorded $17.9 million of income from provider relief fund on the consolidated statement of operations related to PHSSE funds received in 2021. The remaining unrecognized funds of $6.3 million are included in other accrued liabilities on the consolidated balance sheet at December 31, 2021.

During the second quarter of 2020, the Company recorded $18.1 million of income from provider relief fund in the consolidated statement of operations related to $19.7 million received from the PHSSE Fund during the quarter. This was subsequently reversed during the third quarter of 2020. During the fourth quarter of 2020, the Company recorded $32.8 million of income from provider relief fund in the consolidated statement of operations related to $34.9 million of PHSSE funds received from April through December 2020. The Company’s recognition of this income was based on revised guidance in the Consolidated Appropriations Act, 2021 (“CAA”) enacted in December 2020. The Company continues to evaluate its compliance with the terms and conditions to, and the financial impact of, funds received under the CARES Act and other government relief programs.

The CARES Act also provides for certain federal income and other tax changes, including an increase in the interest expense tax deduction limitation and bonus depreciation of qualified improvement property. Furthermore, under the CARES Act, (i) for taxable years beginning before 2021, net operating loss (“NOL”) carryforwards and carrybacks may offset 100% of taxable income and (ii) NOLs arising in 2018, 2019 and 2020 taxable years may be carried back to each of the preceding five years to generate a refund. As a result, in 2019 and 2020 the Company received a benefit, in the form of refunds and lower future tax payments, of $51.6 million, consisting of $22.8 million related to interest expense, $20.5 million related to qualified improvement property legislation and an $8.3 million permanent benefit due to the loss being able to be carried back at a 35% tax rate to offset income in tax years prior to 2018 (21% for tax years after 2017). The Company also received a cash benefit of approximately $39 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes, as enacted by the CARES Act. The Company repaid half of the $39 million of payroll tax deferrals during the third quarter of 2021 and expects to repay the remaining portion in the second half of 2022.

Long-Term Debt

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Long-Term Debt

11. Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31,
	2021			2020
New Credit Facility:
Term Loan A	$	417,031		$	—
Revolving Line of Credit		170,000			—
Prior Credit Facility:
Senior Secured Term A Loan		—			311,733
Senior Secured Term B Loans		—			872,870
5.625% Senior Notes due 2023		—			650,000
6.500% Senior Notes due 2024		—			390,000
5.500% Senior Notes due 2028		450,000			450,000
5.000% Senior Notes due 2029		475,000			475,000
Other long-term debt		—			3,625
Less: unamortized debt issuance costs, discount and premium		(14,811	)		(30,802	)
		1,497,220			3,122,426
Less: current portion		(18,594	)		(153,478	)
Long-term debt	$	1,478,626		$	2,968,948

New Credit Facility

The Company entered into a new senior credit facility (the “New Credit Facility”) on March 17, 2021. This New Credit Facility provides for a $600.0 million senior secured revolving credit facility (the “Revolving Facility”) and a $425.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Facility, the “Senior Facilities”), each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $20.0 million to be utilized for the issuance of letters of credit and (ii) the availability of a swingline facility under which the Company may borrow up to $20.0 million.

As a part of the closing of the New Credit Facility on March 17, 2021, the Company (i) refinanced and terminated the Company’s prior credit facilities under the Amended and Restated Credit Agreement, dated as of December 31, 2012 (the “Prior Credit Facility”) and (ii) financed the redemption of all of the Company’s outstanding 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”).

The Company had $426.9 million of availability under the Revolving Facility and had standby letters of credit outstanding of $3.1 million related to security for the payment of claims required by its workers’ compensation insurance program at December 31, 2021.

During the third quarter of 2021, the Company repaid $60.0 million of the initial $160.0 million balance outstanding on the Revolving Facility. During the fourth quarter of 2021, the Company had a draw of $70.0 million on the Revolving Facility related to the CenterPointe acquisition.

The New Credit Facility requires quarterly principal repayments for the Term Loan Facility of $2.7 million for March 31, 2022, $5.3 million for June 30, 2022 to March 31, 2024, $8.0 million for June 30, 2024 to March 31, 2025, $10.6 million for June 30, 2025 to December 31, 2025, with the remaining principal balance of the Term Loan Facility due on the maturity date of March 17, 2026.

The Company has the ability to increase the amount of the Senior Facilities, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities (collectively, the “Incremental Facilities”), upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of $480.0 million and an amount equal to 100% of the Consolidated EBITDA (as defined in the New Credit Facility) of the Company and its Restricted Subsidiaries (as defined in the New Credit Facility) (as determined for the four fiscal quarter period most recently ended for which financial statements are available), and (ii) additional amounts so long as, after giving effect thereto, the Consolidated Senior Secured Net Leverage Ratio (as defined in the New Credit Facility) does not exceed 3.5 to 1.0.

Subject to certain exceptions, substantially all of the Company’s existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of the Company’s obligations under the New Credit Facility. Borrowings under the Senior Facilities bear interest at a floating rate, which will initially be, at the Company’s option, either (i) adjusted LIBOR plus 1.75% or (ii) an alternative base rate plus 0.75% (in each case, subject to adjustment based on the Company’s consolidated total net leverage ratio). An unused fee initially set at 0.25% per annum (subject to adjustment based on the Company’s consolidated total net leverage ratio) is payable quarterly in arrears based on the actual daily undrawn portion of the commitments in respect of the Revolving Facility.

The New Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the New Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 5.0 to 1.0 and an interest coverage ratio of at least 3.0 to 1.0. The New Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Senior Facilities may be accelerated and/or the lenders’ commitments terminated. At December 31, 2021, the Company was in compliance with such covenants.

Prior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into the Prior Credit Facility which amended and restated the Senior Secured Credit Facility. The Company amended the Prior Credit Facility from time to time as described in the Company’s prior filings with the SEC.

On February 6, 2019, the Company entered into the Eleventh Amendment (the “Eleventh Amendment”) to the Amended and Restated Credit Agreement. The Eleventh Amendment, among other things, amended the definition of “Consolidated EBITDA” to remove the cap on non-cash charges, losses and expenses related to the impairment of goodwill, which in turn provided increased flexibility to the Company in terms of the Company’s financial covenants.

On February 27, 2019, the Company entered into the Twelfth Amendment (the “Twelfth Amendment”) to the Amended and Restated Credit Agreement. The Twelfth Amendment, among other things, modified certain definitions, including “Consolidated EBITDA”, and increased the Company’s permitted Maximum Consolidated Leverage Ratio, thereby providing increased flexibility to the Company in terms of the Company’s financial covenants

On April 21, 2020, the Company entered into the Thirteenth Amendment (the “Thirteenth Amendment”) to the Prior Credit Facility. The Thirteenth Amendment amended the Consolidated Leverage Ratio in the prior covenant to increase such leverage ratio for the rest of 2020.

On November 13, 2020, the Company entered into the Fourth Repricing Facilities Amendment (the “Fourth Repricing Facilities Amendment”) to the Prior Credit Facility. The Fourth Repricing Facilities Amendment extended the maturity date of each of the prior revolving line of credit and the prior Term Loan A Facility (“TLA Facility”) from November 30, 2021 to November 30, 2022. The Fourth Repricing Facilities Amendment also (1) replaced the revolving line of credit in an aggregate committed amount of $500.0 million with an aggregate committed amount of approximately $459.0 million and (2) replaced the TLA Facility aggregate outstanding principal amount of approximately $352.4 million with an aggregate principal amount of approximately $318.9 million. The interest rate margin applicable to both facilities remained unchanged from the prior facilities, and the commitment fee applicable to the new revolving line of credit also remained unchanged from the prior revolving line of credit. In connection with the Fourth Repricing Facilities Amendment, the Company recorded a debt extinguishment charge of $1.0 million, including the write-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statement of operations for the year ended December 31, 2020.

On January 5, 2021, the Company made a voluntary payment of $105.0 million on the Term Loan B Facility Tranche B-4 (“Tranche B-4 Facility”). On January 19, 2021, the Company used a portion of the net proceeds from the U.K. Sale to repay the outstanding balances of $311.7 million of the TLA Facility and $767.9 million of the Tranche B-4 Facility of the Prior Credit Facility. At March 31, 2021, in connection with the termination of the Prior Credit Facility, the Company recorded a debt extinguishment charge of $10.9 million, including the write-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statement of operations.

Senior Notes

5.500% Senior Notes due 2028

On June 24, 2020, the Company issued $450.0 million of 5.500% Senior Notes due 2028 (the “5.500% Senior Notes”). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021.

5.000% Senior Notes due 2029

On October 14, 2020, the Company issued $475.0 million of 5.000% Senior Notes due 2029 (the “5.000% Senior Notes”). The 5.000% Senior Notes mature on April 15, 2029 and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021. The Company used the net proceeds of the 5.000% Senior Notes to prepay approximately $453.3 million of the outstanding borrowings on the Company’s existing Term Loan B Facility Tranche B-3 (“Tranche B-3 Facility”) and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with the offering. In connection with the 5.000% Senior Notes, the Company recorded a debt extinguishment charge of $2.9 million, including the write-off of discount and deferred financing costs of the Tranche B-3 Facility, which was recorded in debt extinguishment costs in the consolidated statement of operations for the year ended December 31, 2020.

The indentures governing the 5.500% Senior Notes and the 5.000% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the New Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes. On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company had outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes were to mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On March 17, 2021, the Company redeemed the 5.625% Senior Notes.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes were to mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. On March 1, 2021, the Company redeemed the 6.500% Senior Notes.

Redemption of 5.625% Senior Notes and 6.500% Senior Notes

On January 29, 2021, the Company issued conditional notices of full redemption providing for the redemption in full of $650 million of 5.625% Senior Notes and $390 million of 6.500% Senior Notes to the holders of such notes.

On March 1, 2021, the Company satisfied and discharged the indentures governing the 6.500% Senior Notes. In connection with the redemption of the 6.500% Senior Notes, the Company recorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the consolidated statement of operations.

On March 17, 2021, the Company satisfied and discharged the indentures governing the 5.625% Senior Notes. In connection with the redemption of the 5.625% Senior Notes, the Company recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the consolidated statement of operations.

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes were to mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. On June 24, 2020, the Company redeemed the 6.125% Senior Notes.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes were to mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. On June 24, 2020, the Company redeemed the 5.125% Senior Notes.

Redemption of 6.125% Senior Notes and 5.125% Senior Notes

On June 10, 2020, the Company issued conditional notices of full redemption providing for the redemption in full of the 6.125% Senior Notes and 5.125% Senior Notes on July 10, 2020 (the “Redemption Date”), in each case at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including the Redemption Date (the “Redemption Price”). On June 24, 2020, the Company satisfied and discharged the indentures governing the 6.125% Senior Notes and the 5.125% Senior Notes by irrevocably depositing with a trustee sufficient funds equal to the Redemption Price for the 6.125% Senior Notes and the 5.125% Senior Notes and otherwise complying with the terms in the indentures relating to the satisfaction and discharge of the 6.125% Senior Notes and the 5.125% Senior Notes. In connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, the Company recorded a debt extinguishment charge of $3.3 million, including the write-off of the deferred financing and other costs in the consolidated statement of operations for the year ended December 31, 2020.

Other long-term debt

During the year ended December 31, 2021, the Company repaid other long-term debt of $3.3 million, which is reflected in repayment of long-term debt within financing activities in the consolidated statement of cash flows.

Debt Issuance Costs

Debt issuance costs are deferred and amortized to interest expense over the term of the related debt. Debt issuance costs at December 31, 2021 were $14.8 million, net of accumulated amortization of $2.4 million. Debt issuance costs at December 31, 2020 were $29.8 million, net of accumulated amortization of $56.0 million. Amortization expense related to debt issuance costs, which is included in interest expense on the consolidated statements of operations, was $2.8 million, $9.8 million and $9.7 million, respectively, for the years ended December 31, 2021, 2020 and 2019.

Other

The aggregate maturities of long-term debt at December 31, 2021 were as follows (in thousands):

2022	$	18,594
2023		21,250
2024		29,219
2025		39,843
2026		478,125
Thereafter		925,000
Total	$	1,512,031

Noncontrolling Interests

12 Months Ended

Dec. 31, 2021

Noncontrolling Interest [Abstract]

Noncontrolling Interests

12. Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At December 31, 2021, the Company operated six facilities through non-wholly owned subsidiaries. The Company owns between approximately 60% and 86% of the equity interests of these entities and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions. The Company consolidates the operations of each facility based on its status as primary beneficiary, as further discussed in Note 13 – Variable Interest Entities. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2020	$	33,151
Acquisition of redeemable noncontrolling interests		20,147
Net income attributable to noncontrolling interests		2,933
Distributions to noncontrolling interests		(916	)
Balance at December 31, 2020		55,315
Acquisition of redeemable noncontrolling interests		6,734
Net income attributable to noncontrolling interests		4,927
Distributions to noncontrolling interests		(1,588	)
Balance at December 31, 2021	$	65,388

Variable Interest Entities

12 Months Ended

Dec. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Variable Interest Entities

13. Variable Interest Entities

For legal entities where the Company has a financial relationship, the Company evaluates whether it has a variable interest and determines if the entity is considered a variable interest entity (“VIE”). If the Company concludes an entity is a VIE and the Company is the primary beneficiary, the entity is consolidated. The primary beneficiary analysis is a qualitative analysis based on power and benefits. A reporting entity has a controlling financial interest in a VIE and must consolidate the VIE if it has both power and benefits. It must have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.

At December 31, 2021, the Company operated six facilities through non-wholly owned subsidiaries. The Company owns between approximately 60% and 86% of the equity interests of these entities, and noncontrolling partners own the remaining equity interests. The Company manages each of these facilities, is responsible for the day to day operations and, therefore, has the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These activities include, but are not limited to, behavioral healthcare services, human resource and employment-related decisions, marketing and finance. The terms of the agreements governing each of the Company’s VIEs prohibit the Company from using the assets of each VIE to satisfy the obligations of other entities. Consolidated assets at December 31, 2021 and 2020 include total assets of variable interest entities of $320.6 million and $261.7 million, respectively, which cannot be used to settle the obligations of other entities. Consolidated liabilities at December 31, 2021 and 2020 include total liabilities of variable interest entities of $24.1 million and $26.1 million, respectively.

The consolidated VIEs assets and liabilities in the Company’s consolidated balance sheets are shown below (in thousands):

	December 31,
	2021		2020
Cash and cash equivalents	$	26,360	$	15,151
Accounts receivable, net		20,144		18,507
Other current assets		1,304		1,461
Total current assets		47,808		35,119
Property and equipment, net		220,793		175,103
Goodwill		34,945		34,945
Intangible assets, net		10,490		9,581
Operating lease right-of-use assets		6,603		6,909
Total assets	$	320,639	$	261,657


Accounts payable	$	3,690	$	4,143
Accrued salaries and benefits		5,656		4,357
Current portion of operating lease liabilities		197		164
Other accrued liabilities		6,818		8,366
Total current liabilities		16,361		17,030
Operating lease liabilities		6,666		6,863
Other liabilities		1,083		2,166
Total liabilities	$	24,110	$	26,059

Accumulated Other Comprehensive Loss

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Accumulated Other Comprehensive Loss

14. Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2019	$	(504,528	)	$	43,966		$	(1,815	)	$	(462,377	)
Foreign currency translation gain (loss)		69,895			—			(84	)		69,811
Loss on derivative instruments, net of tax of $(3.6) million		—			(19,008	)		—			(19,008	)
Pension liability adjustment, net of tax of $(0.6) million		—			—			(3,310	)		(3,310	)
Balance at December 31, 2019		(434,633	)		24,958			(5,209	)		(414,884	)
Foreign currency translation gain (loss)		61,532			—			(285	)		61,247
Loss on derivative instruments, net of tax of $(3.9) million		—			(11,272	)		—			(11,272	)
Pension liability adjustment, net of tax of $(0.8) million		—			—			(6,456	)		(6,456	)
Balance at December 31, 2020		(373,101	)		13,686			(11,950	)		(371,365	)
Foreign currency translation (loss) gain		(4,293	)		—			33			(4,260	)
Gain on derivative instruments, net of tax of $0.1 million		—			19			—			19
U.K. Sale		377,394			(13,705	)		11,917			375,606
Balance at December 31, 2021	$	—		$	—		$	—		$	—

Equity

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Equity

15. Equity

Preferred Stock

The Company’s amended and restated certificate of incorporation provides that up to 10,000,000 shares of preferred stock may be issued. The board of directors has the authority to issue preferred stock in one or more series and to fix for each series the voting powers (full, limited or none), and the designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions on the stock and the number of shares constituting any series and the designations of this series, without any further vote or action by the stockholders.

Common Stock

The Company’s amended and restated certificate of incorporation provides that up to 180,000,000 shares of common stock may be issued. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. There are no preemptive, conversion, redemption or sinking fund provisions applicable to shares of the Company’s common stock. In the event of liquidation, dissolution or winding up, holders of the Company’s common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the New Credit Facility imposes restrictions on the Company’s ability to pay dividends.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Equity-Based Compensation

12 Months Ended

Dec. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

16. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At December 31, 2021, a maximum of 12,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 4,481,404 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire

award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the closing price of the Company’s common stock on the most recent trading date prior to the date of grant.

The Company recognized $37.5 million, $22.5 million and $17.3 million in equity-based compensation expense for the years ended December 31, 2021, 2020 and 2019, respectively. Stock compensation expense for the years ended December 31, 2021, 2020 and 2019 is impacted by forfeiture adjustments and restricted stock unit adjustments based on actual performance compared to vesting targets. At December 31, 2021, there was $39.8 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.2 years.

At December 31, 2021, there were no warrants outstanding. The Company recognized a deferred income tax benefit of $9.6 million, $5.5 million and $4.0 million for the years ended December 31, 2021, 2020 and 2019, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 2019, 2020 and 2021 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2019		1,199,540		$	44.64		7.26	$	2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068			39.40		7.57		1,650
Options granted		507,600			33.13		9.18		157
Options exercised		(68,700	)		29.15	N/A			854
Options cancelled		(288,662	)		39.67	N/A		N/A
Options outstanding at December 31, 2020		1,510,306			37.56		7.35		1,414
Options granted		324,320			57.53		9.31		851
Options exercised		(558,322	)		39.45	N/A			11,118
Options cancelled		(170,235	)		40.08	N/A		N/A
Options outstanding at December 31, 2021		1,106,069		$	42.07		7.49	$	19,988
Options exercisable at December 31, 2020		596,606		$	45.37		5.55	$	543
Options exercisable at December 31, 2021		324,409		$	43.24		5.48	$	5,575

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2021, 2020 and 2019:

	Year Ended December 31,
	2021			2020			2019
Weighted average grant-date fair value of options	$	20.64		$	12.37		$	17.59
Risk-free interest rate		0.9	%		1.6	%		2.4	%
Expected volatility		40	%		41	%		38	%
Expected life (in years)		5.0			5.0			5.0

The Company’s estimate of expected volatility for stock options is based upon the volatility of its stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U. S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock activity during 2019, 2020 and 2021 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14
Granted		637,312			25.82
Cancelled		(129,683	)		34.56
Vested		(289,769	)		35.88
Unvested at December 31, 2020		1,022,996		$	28.41
Granted		352,430			58.32
Cancelled		(82,751	)		39.63
Vested		(366,048	)		30.81
Unvested at December 31, 2021		926,627		$	37.84

Restricted stock unit activity during 2019, 2020 and 2021 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89
Granted		583,680			10.60
Performance adjustment		117,772			13.50
Cancelled		(63,056	)		43.35
Vested		(12,691	)		42.09
Unvested at December 31, 2020		1,073,062		$	20.15
Granted		149,416			61.52
Performance adjustment		465,993			25.49
Cancelled		—			—
Vested		(184,051	)		42.30
Unvested at December 31, 2021		1,504,420		$	23.20

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets and Company performance compared to peers. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the two- or three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. Additionally, the number of shares issuable pursuant to restricted stock units granted during 2020 and 2019 are subject to adjustment based on the Company’s three-year annualized total stockholder return relative to a peer group consisting of S&P 1500 companies within the Healthcare Providers & Services 6 digit GICS industry group and selected other companies deemed to be peers. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company’s actual performance compared to the targets and, for 2020 and 2019 awards, performance compared to peers.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions.

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

17. Income Taxes

Provision for income taxes consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2021			2020			2019
Current:
Federal	$	48,292		$	(18,215	)	$	18,954
State		6,715			4,981			3,440
Foreign		778			732			1,602
Total current		55,785			(12,502	)		23,996
Deferred:
Federal		13,339			46,442			(1,572	)
State		(1,892	)		564			2,509
Foreign		325			6,102			152
Total deferred provision		11,772			53,108			1,089
Provision for income taxes	$	67,557		$	40,606		$	25,085

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2021			2020			2019
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		21.0	%
Impact of foreign operations		1.7			(0.5	)		1.1
Effects of statutory rate change		—			3.2			—
State income taxes, net of federal tax effect		3.9			5.1			5.8
Permanent differences		1.7			1.5			3.3
Change in valuation allowance		(2.8	)		127.4			0.6
Unrecognized tax benefit release		(0.9	)		(0.4	)		0.5
Federal tax credits		(0.8	)		(1.0	)		(2.2	)
Basis recognition related to foreign divestiture		—			(129.9	)		—
CARES Act impacts to net operating losses		—			(4.5	)		—
Other		0.7			0.2			1.9
Effective income tax rate		24.5	%		22.1	%		32.0	%

For the year ended December 31, 2021, the provision for income taxes was $67.6 million, reflecting an effective tax rate of 24.5%, compared to $40.6 million, reflecting an effective tax rate of 22.1%, for the year ended December 31, 2020. The increase in the effective tax rate for the year ended December 31, 2021 was primarily attributable to the Company’s recognition of a deferred tax liability as a result of the Company’s previous permanent reinvestment assertion and non-recurring impacts of the U.S. and U.K. tax legislation enacted in 2020.

The domestic and foreign components of income from continuing operations before income taxes for continuing operations are as follows (in thousands):

	Year Ended December 31,
	2021		2020		2019
Foreign	$	5,596	$	9,904	$	6,070
Domestic		270,164		173,893		72,325
Income from continuing operations before income taxes	$	275,760	$	183,797	$	78,395

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 2021 and December 31, 2020 were as follows (in thousands):

	December 31,
	2021			2020
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	9,354		$	7,486
Capital loss carryovers (a)		215,367			239,269
Bad debt allowance		1,083			1,243
Accrued compensation and severance		18,241			20,889
Insurance reserves		18,847			18,497
Leases		896			846
Accrued expenses		5,768			11,817
Interest carryforwards		3,396			3,374
Lease right-of-use liabilities		26,154			24,402
Other assets		8,066			13,251
Total gross deferred tax assets		307,172			341,074
Less: valuation allowance		(217,325	)		(241,225	)
Deferred tax assets		89,847			99,849
Deferred tax liabilities:
Fixed asset basis difference		(2,456	)		(5,553	)
Prepaid items		(2,882	)		(2,960	)
Intangible assets		(126,446	)		(115,196	)
Lease right-of-use assets		(24,660	)		(22,948	)
Investment in foreign subsidiary		(4,691	)		—
Total deferred tax liabilities		(161,135	)		(146,657	)
Total net deferred tax liability	$	(71,288	)	$	(46,808	)

(a)	The presentation of the December 31, 2020 deferred tax liability attributable to the U.K. divestiture has been adjusted to reflect the final outcome of the sale.

The Company established a deferred tax asset, during 2020, related to the Company’s investment in a foreign subsidiary in the amount of $239.1 million, in anticipation of the Company’s divestiture of the U.K. business on January 19, 2021. The Company concluded a full valuation allowance of this deferred tax asset was required as the Company expected the finalization of the divestiture to result in a capital loss. In 2021, upon the closing of the transaction, the Company recorded adjustments to its previous estimates of the capital loss, resulting in a tax benefit of $7.5 million to account for current year transactions and certain state jurisdictions where the tax benefit from the U.K. loss is projected to be realized. The Company concluded that a full valuation allowance on the remaining capital loss of $215.4 million was necessary due to the limitations in realizing the asset via offsetting capital gains in the future.

For the year ended December 31, 2021, the Company determined and asserts that the current and accumulated earnings from foreign operations are no longer indefinitely reinvested, and a deferred tax liability was established on the current and accumulated undistributed earnings of the Company’s continuing foreign operations within Puerto Rico in the amount of $4.6 million, resulting in an income tax expense in the current year. This deferred tax liability was not recognized in prior years under the exception within ASC 740-30-25-18 that limits the recognition of deferred tax liabilities for the excess of book basis over tax basis in an investment in a subsidiary in instances when the Company is permanently reinvested.

The Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. At December 31, 2021 and 2020, the Company carried a valuation allowance against deferred tax assets of $217.3 million and $241.2 million, respectively. These amounts are primarily related to deferred tax assets related to the Company’s capital loss carryforward resulting from the U.K. Sale and certain state net operating losses.

As of December 31, 2021 and 2020, the Company had no federal net operating loss carryforwards. The foreign net operating loss carryforwards at December 31, 2021 and 2020 are approximately $0.1 million and $0.1 million, respectively, and have no expiration.

The Company has state net operating loss carryforwards at December 31, 2021 and 2020 of approximately $227.3 million and $170.0 million, respectively. The increase in net operating loss carryforwards from prior year results from states that do not distinguish losses as either capital or ordinary in nature; therefore, the Company is able to deduct the loss on the sale of its U.K. operations. These net operating loss carryforwards, if not used to offset future taxable income, will expire from 2022 to 2035. In addition, the Company has certain state tax credits of $0.4 million which will begin to expire in 2030 if not utilized.

Income taxes receivable was $24.6 million and $0.9 million at December 31, 2021 and 2020, respectively. At December 31, 2021, $23.1 million of income taxes receivable has been included in other assets due to anticipated delays in receipt of income tax refunds associated with amended tax return filings. The remaining $1.5 million of income taxes receivable is included in other current assets in the December 31, 2021 consolidated balance sheet. Income taxes payable of $5.5 million and $16.3 million at December 31, 2021 and 2020, respectively, was included in other accrued liabilities in the consolidated balance sheets. The decrease in the payable for the year ended December 31, 2021 was primarily attributable to tax payments in excess of accruals and the income tax benefit derived from the Company's accelerated repayment of $18.5 million of CARES payroll tax deferrals taken on the 2020 U.S. jurisdictional filings.

The Company recorded income taxes payable related to unrecognized tax benefits of $0.0 million and $2.5 million at December 31, 2021 and December 31, 2020, respectively. These amounts are inclusive of any interest and penalties, which is included in other liabilities on the consolidated balance sheets. A reconciliation of the beginning and ending amount of unrecognized income tax benefits, exclusive of any interest and penalties, net of the federal benefit, is as follows (in thousands):

	2021			2020
Balance at January 1	$	2,060		$	2,441
Additions based on tax positions related to the current year		—			—
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(2,060	)		(381	)
Balance at December 31	$	—		$	2,060

At December 31, 2021 and 2020, the cumulative amounts of interest and penalties recognized were $0.0 million and $0.5 million, respectively. Unrecognized tax benefits of $2.1 million would affect the effective rate if recognized during the current year as a result of a lapse of the statute of limitations and settlements with taxing authorities.

The Company and its subsidiaries file income tax returns in federal and in many state and local jurisdictions as well as foreign jurisdictions. The Company may be subject to examination by the Internal Revenue Service (“IRS”) for calendar year 2018 through 2020. Additionally, any net operating losses that were generated in prior years and utilized in these years may also be subject to examination by the IRS. While no other foreign jurisdictions are presently under examination, the Company may be subject to examination for calendar years 2017 through 2020. Generally, for state tax purposes, the Company’s 2015 through 2020 tax years remain open for examination by the tax authorities. At the date of this report there were no audits or inquires that had progressed sufficiently to predict their ultimate outcome.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Derivatives

12 Months Ended

Dec. 31, 2021

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivatives

18. Derivatives

The Company entered into foreign currency forward contracts during the year ended December 31, 2020 in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between U.S. Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

In August 2019, the Company also entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £538.1 million. During the term of the swap agreements, the Company received semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company made semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements resulted in £25.4 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million.

In conjunction with the U.K. Sale in January 2021, the Company settled its cross currency swap liability and outstanding forward contracts. Cash paid for the settlement of the cross currency swap agreements and forward contracts outstanding at December 31, 2020 are included in investing activities on the consolidated statement of cash flows.

The Company designated the cross currency swap agreements and forward contracts entered into during 2020 as qualifying hedging instruments and accounted for these derivatives as net investment hedges. The fair value of these derivatives at December 31, 2020 of $84.6 million is recorded as derivative instrument liabilities in the consolidated balance sheet. During 2019, the Company elected the spot method for recording its net investment hedges. Gains and losses resulting from the settlement of the excluded components were recorded in interest expense on the consolidated statement of operations. Gains and losses resulting from fair value adjustments to the cross currency swap agreements were recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. These gains and losses were considered in the carrying value of the U.K. operations and included in the loss on the U.K. Sale recorded in December 31, 2020 and January 2021. Prior to the U.K. Sale, cash flows related to the cross currency swap derivatives are included in operating activities in the consolidated statements of cash flows.

Fair Value Measurements

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

19. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s New Credit Facility, Prior Credit Facility, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes, 5.000% Senior Notes, other long-term debt and derivative instrument liabilities at December 31, 2021 and 2020 were as follows (in thousands):

	Carrying Amount				Fair Value
	December 31,				December 31,
	2021		2020		2021		2020
New Credit Facility	$	584,418	$	—	$	584,418	$	—
Prior Credit Facility	$	—	$	1,175,437	$	—	$	1,175,437
5.625% Senior Notes due 2023	$	—	$	646,344	$	—	$	647,960
6.500% Senior Notes due 2024	$	—	$	385,636	$	—	$	393,850
5.500% Senior Notes due 2028	$	443,894	$	443,139	$	466,577	$	475,931
5.000% Senior Notes due 2029	$	468,907	$	468,245	$	481,802	$	499,852
Other long-term debt	$	—	$	3,625	$	—	$	3,625
Derivative instrument liabilities	$	—	$	84,584	$	—	$	84,584

The Company’s New Credit Facility, Prior Credit Facility, 5.625% Senior Notes, 6.500% Senior Notes, 5.500% Senior Notes, 5.000% Senior Notes and other long-term debt were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair values of the derivative instrument liabilities were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

20. Commitments and Contingencies

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of Tennessee. The complaint purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. At this time, the Company is not able to quantify any potential liability in connection with this litigation because the case is in its early stages.

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Joey A. Jacobs, et al., Case No. 3:19-cv-00167, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated. On February 16, 2021, the parties filed a stipulation staying the case. On October 23, 2020, a purported stockholder filed a third related derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Pfenning v. Jacobs, et al., Case No. 2020-0915-JRS, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. At this time, the Company is not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.

On April 25, 2018, plaintiff filed Pence v. Sober Living By the Sea, Inc. - 30-2018-00988742-CU-OE-CXC, Orange County Superior Court (Pence I). On July 13, 2018, plaintiff next filed Pence v. Sober Living by the Sea, Inc.; Acadia Healthcare Company, Inc. - 30-2018-01005317-CU-OE-CJC, Orange County Superior Court (Pence II). These cases have now been consolidated before the same judge in the Complex Litigation Department of the Orange County Superior Court. The complaints allege various wage and hour violations under California law on behalf of a putative class of all non-exempt California employees of Acadia and various subsidiaries, going back to April 25, 2014, and on behalf of purportedly aggrieved non-exempt employees under California’s Private Attorney General Act (“PAGA”). The claims include (1) failure to provide overtime wages; (2); failure to provide minimum wages; (3) failure to provide meal periods; (4) failure to provide rest periods; (5); failure to pay wages due at termination; (6) failure to provide accurate wage statements; (7) violations of California Business and Professions Code section 17200; and (8) civil penalties under California Labor Code section 2699 (PAGA). During the second quarter of 2020, the Company recorded approximately $4.0 million to transaction-related expenses in the consolidated statement of operations based on the Company’s expected settlement and legal fees. The court granted final approval of the settlement in September 2021, and the Company made the settlement payment in October 2021.

In the fall of 2017, the Office of Inspector General (“OIG”) issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the OIG issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company is cooperating with the government’s investigation but is not able to quantify any potential liability in connection with these investigations.

Employee Benefit Plans

12 Months Ended

Dec. 31, 2021

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

21. Employee Benefit Plans

The Company maintains a qualified defined contribution 401(k) plan covering substantially all of its employees in the U.S. The Company may, at its discretion, make contributions to the plan. The Company recorded expense of $2.8 million, $3.8 million and $4.1 million related to the 401(k) plan for the years ended December 31, 2021, 2020 and 2019, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Financial Information Combined Wholly-Owned Subsidiaries

12 Months Ended

Dec. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Financial Information Combined Wholly-Owned Subsidiaries

22. Financial Information Combined Wholly-Owned Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 5.500% Senior Notes and the 5.000% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the New Credit Facility. The 5.625% Senior Notes, the 6.500% Senior Notes, the 5.500% Senior Notes and the 5.000% Senior Notes were all jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guaranteed the Company’s obligations under the Prior Credit Facility. Summarized financial information presented below is consistent with the consolidated financial statements of the Company, except transactions between combining entities have been eliminated. Financial information for the combined non-guarantor entities has been excluded. Presented below is financial information for the combined wholly-owned subsidiary guarantors at December 31, 2021 and 2020, and for the year ended December 31, 2021.

Summarized balance sheet information (in thousands):

	December 31,
	2021		2020
Current assets	$	422,113	$	654,735
Property and equipment, net		1,525,569		1,421,875
Goodwill		2,086,978		1,992,305
Total noncurrent assets		3,893,087		3,640,809

Current liabilities		385,044		626,419
Long-term debt		1,460,046		2,786,125
Total noncurrent liabilities		1,752,271		3,045,981
Redeemable noncontrolling interests		—		—
Total equity		2,177,885		623,144

Summarized operating results information (in thousands):

	For the Year Ended December 31, 2021
Revenue	$	2,132,637
Income from continuing operations before income taxes		246,473
Net income		184,785
Net income attributable to Acadia Healthcare Company, Inc.		184,785

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Cash and Cash Equivalents

Insurance

Property and Equipment and Other Long-Lived Assets

Goodwill and Indefinite-Lived Intangible Assets

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2021		2020
Prepaid expenses	$	22,292	$	19,480
Assets held for sale		15,808		—
Workers’ compensation deposits – current portion		12,000		12,000
Insurance receivable – current portion		10,807		6,792
Other receivables		10,786		10,025
Inventory		4,786		4,851
Income taxes receivable		1,523		897
Cost report receivable		—		5,818
Other		1,884		1,469
Other current assets	$	79,886	$	61,332

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2021		2020
Unearned income	$	30,371	$	35,946
Accrued expenses		26,791		28,452
Accrued interest		17,418		40,479
Government relief funds		12,718		5,495
Insurance liability – current portion		11,923		9,700
Accrued property taxes		8,375		6,763
Cost report payable		6,487		—
Income taxes payable		5,540		16,345
Finance lease liabilities		990		32,188
Other		5,886		3,085
Other accrued liabilities	$	126,499	$	178,453

Stock Compensation

Earnings Per Share

Income Taxes

Recent Accounting Pronouncements

2018. Early adoption is permitted. The Company adopted ASU 2017-12 on January 1, 2019. There is no significant impact on the Company’s consolidated financial statements.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2021		2020
Prepaid expenses	$	22,292	$	19,480
Assets held for sale		15,808		—
Workers’ compensation deposits – current portion		12,000		12,000
Insurance receivable – current portion		10,807		6,792
Other receivables		10,786		10,025
Inventory		4,786		4,851
Income taxes receivable		1,523		897
Cost report receivable		—		5,818
Other		1,884		1,469
Other current assets	$	79,886	$	61,332

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2021		2020
Unearned income	$	30,371	$	35,946
Accrued expenses		26,791		28,452
Accrued interest		17,418		40,479
Government relief funds		12,718		5,495
Insurance liability – current portion		11,923		9,700
Accrued property taxes		8,375		6,763
Cost report payable		6,487		—
Income taxes payable		5,540		16,345
Finance lease liabilities		990		32,188
Other		5,886		3,085
Other accrued liabilities	$	126,499	$	178,453

U.K. Sale (Tables)

12 Months Ended

Dec. 31, 2021

Discontinued Operations And Disposal Groups [Abstract]

Schedule of Financial Condition, Results of Operations and Cash Flows of U.K. Operations as Discontinued Operations

For the years ended December 31, 2021, 2020 and 2019, results of operations of the U.K. operations were as follows (in thousands):

	Year Ended December 31,
	2021			2020			2019
Revenue	$	62,520		$	1,119,768		$	1,099,081
Salaries, wages and benefits		35,937			632,134			609,823
Professional fees		6,815			127,291			122,532
Supplies		2,217			38,285			37,527
Rents and leases		2,509			47,748			46,743
Other operating expenses		6,682			113,534			115,897
Depreciation and amortization		—			74,935			76,121
Interest expense, net		10			(417	)		(231	)
Loss on sale		13,490			867,324			—
Loss on impairment		—			20,239			27,169
Transaction-related expenses		6,265			8,719			5,907
Total expenses		73,925			1,929,792			1,041,488
(Loss) income from discontinued operations before income taxes		(11,405	)		(810,024	)		57,593
Provision for income taxes		1,236			2,366			781
(Loss) income from discontinued operations	$	(12,641	)	$	(812,390	)	$	56,812

The major classes of assets and liabilities for the U.K. operations as of December 31, 2020 are shown below (in thousands):

Cash and cash equivalents	$	75,051
Accounts receivable, net		52,196
Other current assets		13,361
Current assets of discontinued operations		140,608
Property and equipment, net		1,297,923
Goodwill		—
Intangible assets, net		22,289
Operating lease right-of-use assets		341,289
Other assets		7,706
Total assets of discontinued operations		1,809,815

Current liabilities:
Accounts payable	$	44,929
Current portion of operating lease liabilities		11,141
Other current liabilities		136,895
Current liabilities of discontinued operations		192,965
Operating lease liabilities		387,607
Deferred tax liabilities		57,230
Other liabilities		22,225
Total liabilities of discontinued operations	$	660,027

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Revenue (Tables)

12 Months Ended

Dec. 31, 2021

Revenue From Contract With Customer [Abstract]

Schedule of Revenue Attributed to Each Category

The table below presents total U.S. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2021		2020		2019
Acute inpatient psychiatric facilities	$	1,126,872	$	984,609	$	912,097
Specialty treatment facilities		896,564		802,022		788,232
Residential treatment centers		283,169		281,158		286,959
Other		7,789		22,140		21,093
Revenue	$	2,314,394	$	2,089,929	$	2,008,381

Schedule of Revenue and Percentage Generated by Each Payor Type in U.S Facilities

The following table presents revenue by payor type and as a percentage of revenue in the Company’s U.S. Facilities for the years ended December 31, 2021, 2020 and 2019 (in thousands):

	Year Ended December 31,
	2021					2020					2019
	Amount		%			Amount		%			Amount		%
Commercial	$	684,292		29.6	%	$	596,698		28.5	%	$	565,350		28.2	%
Medicare		364,598		15.8	%		330,070		15.8	%		294,691		14.7	%
Medicaid		1,147,884		49.6	%		1,037,852		49.7	%		1,007,102		50.1	%
Self-Pay		93,425		4.0	%		98,302		4.7	%		118,716		5.9	%
Other		24,195		1.0	%		27,007		1.3	%		22,522		1.1	%
Revenue	$	2,314,394		100.0	%	$	2,089,929		100.0	%	$	2,008,381		100.0	%

Summary of the Activity in Unearned Revenue in U.S. Facilities

A summary of the activity in contract liabilities is as follows (in thousands):

Balance at December 31, 2020	$	47,196
Payments received		11,739
Revenue recognized		(3,463	)
Medicare advance repayments		(25,101	)
Balance at December 31, 2021	$	30,371

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2021, 2020 and 2019 (in thousands, except per share amounts):

	Year Ended December 31,
	2021			2020			2019
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	203,276		$	140,258		$	52,111
(Loss) income from discontinued operations		(12,641	)		(812,390	)		56,812
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	190,635		$	(672,132	)	$	108,923
Denominator:
Weighted average shares outstanding for basic earnings per share		88,769			87,875			87,612
Effects of dilutive instruments		2,024			720			204
Shares used in computing diluted earnings per common share		90,793			88,595			87,816

Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	2.29		$	1.60		$	0.59
(Loss) income from discontinued operations		(0.14	)		(9.25	)		0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	2.15		$	(7.65	)	$	1.24

Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$	2.24		$	1.58		$	0.59
(Loss) income from discontinued operations		(0.14	)		(9.17	)		0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	2.10		$	(7.59	)	$	1.24

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed

The preliminary fair values of assets acquired and liabilities assumed in the CenterPointe acquisition were as follows (in thousands):

Cash	$	5,640
Accounts receivable, net		10,230
Other current assets		2,087
Property and equipment		35,670
Goodwill		97,122
Intangible assets		825
Deferred tax assets		1,573
Operating lease right-of-use assets		28,858
Total assets acquired		182,005
Accounts payable		3,820
Accrued salaries and benefits		3,585
Current portion of operating lease liabilities		2,582
Other accrued liabilities		1,088
Operating lease liabilities		26,275
Total liabilities assumed		37,350
Net assets acquired	$	144,655

Summary of Changes in Goodwill

The following table summarizes changes in goodwill for the years 2020 and 2021 (in thousands):

Balance at January 1, 2020	$	2,085,104
Increase from contribution of redeemable noncontrolling interests		20,200
Adjustments related to 2019 acquisitions		(40	)
Balance at December 31, 2020		2,105,264
Increase from acquisitions		97,122
2021 dispositions		(2,449	)
Balance at December 31, 2021	$	2,199,937

	Year Ended December 31,
	2021		2020		2019
Legal, accounting and other acquisition-related costs	$	8,315	$	8,252	$	3,030
Termination, restructuring and strategic review costs		4,463		3,468		12,598
Management transition costs		—		—		5,529
	$	12,778	$	11,720	$	21,157

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands):

	December 31,
	2021			2020
Land	$	154,376		$	144,221
Building and improvements		1,683,560			1,490,149
Equipment		253,100			220,690
Construction in progress		221,249			217,479
		2,312,285			2,072,539
Less: accumulated depreciation		(541,126	)		(449,643	)
Property and equipment, net	$	1,771,159		$	1,622,896

Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2021 and 2020 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2021		December 31, 2020		December 31, 2021			December 31, 2020
Intangible assets subject to amortization:
Non-compete agreements	$	1,131	$	1,131	$	(1,131	)	$	(1,131	)

Intangible assets not subject to amortization:
Licenses and accreditations		11,600		11,873		—			—
Trade names		40,435		39,526		—			—
Certificates of need		18,110		17,136		—			—
		70,145		68,535		—			—
Total	$	71,276	$	69,666	$	(1,131	)	$	(1,131	)

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Schedule of Leases on Consolidated Balance Sheet

The Company recorded the following at December 31, 2021 and 2020 on the consolidated balance sheets (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2021		December 31, 2020
Finance lease right-of-use assets	Property and equipment, net	$	8,627	$	34,621
Operating lease right-of-use assets	Operating lease right-of-use assets		133,761		96,937
Total		$	142,388	$	131,558

Lease Liabilities	Balance Sheet Classification	December 31, 2021		December 31, 2020
Current:
Finance lease liabilities	Other accrued liabilities	$	990	$	32,188
Operating lease liabilities	Current portion of operating lease liabilities		23,348		18,916
Noncurrent:
Finance lease liabilities	Other liabilities		10,807		10,744
Operating lease liabilities	Operating lease liabilities		116,841		84,029
Total		$	151,986	$	145,877

Schedule of Weighted-average Remaining Lease Terms and Discount Rates

Weighted-average remaining lease terms and discount rates were as follows at December 31, 2021 and 2020:

	December 31,
	2021			2020
Weighted-average remaining lease term (in years):
Finance	22.9			6.7
Operating	9.1			8.5

Weighted-average discount rate:
Finance		5.1	%		5.9	%
Operating		5.1	%		6.5	%

Schedule of Lease Cost

The Company recorded the following lease costs at December 31, 2021 and 2020 (in thousands):

	December 31,
	2021		2020
Finance lease costs:
Depreciation of leased assets		378		868
Interest of lease liabilities		2,174		3,214
Total finance lease costs	$	2,552	$	4,082

Operating lease costs		28,233		27,050
Variable lease costs		2,488		2,501
Short term lease costs		3,257		3,558
Other lease costs		4,541		4,253
Total rents and leases	$	38,519	$	37,362

Total lease costs	$	41,071	$	41,444

Schedule of Undiscounted Cash Flows for Finance and Operating Leases

Undiscounted cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2021 (in thousands):

	Finance Leases		Operating Leases
2021	$	990	$	29,973
2022		990		26,471
2023		1,007		23,110
2024		1,089		19,730
2025		1,089		14,500
Thereafter		22,911		68,427
Total minimum lease payments		28,076		182,211
Less: amount of lease payments representing interest		16,279		42,022
Present value of future minimum lease payments		11,797		140,189
Less: Current portion of lease liabilities		990		23,348
Noncurrent lease liabilities	$	10,807	$	116,841

Schedule of Supplemental Data

Supplemental data for the years ended December 31, 2021 and 2020 were as follows (in thousands):

	December 31,
	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	27,508	$	26,810
Operating cash flows for finance leases	$	2,174	$	3,214
Financing cash flows for finance leases	$	31,136	$	551

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	63,279	$	21,285
Finance leases	$	—	$	—

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31,
	2021			2020
New Credit Facility:
Term Loan A	$	417,031		$	—
Revolving Line of Credit		170,000			—
Prior Credit Facility:
Senior Secured Term A Loan		—			311,733
Senior Secured Term B Loans		—			872,870
5.625% Senior Notes due 2023		—			650,000
6.500% Senior Notes due 2024		—			390,000
5.500% Senior Notes due 2028		450,000			450,000
5.000% Senior Notes due 2029		475,000			475,000
Other long-term debt		—			3,625
Less: unamortized debt issuance costs, discount and premium		(14,811	)		(30,802	)
		1,497,220			3,122,426
Less: current portion		(18,594	)		(153,478	)
Long-term debt	$	1,478,626		$	2,968,948

Summary of Aggregate Maturities of Long-Term Debt

The aggregate maturities of long-term debt at December 31, 2021 were as follows (in thousands):

2022	$	18,594
2023		21,250
2024		29,219
2025		39,843
2026		478,125
Thereafter		925,000
Total	$	1,512,031

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

+ Details

Noncontrolling Interests (Tables)

12 Months Ended

Dec. 31, 2021

Noncontrolling Interest [Abstract]

Summary of Redeemable Noncontrolling Interests

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2020	$	33,151
Acquisition of redeemable noncontrolling interests		20,147
Net income attributable to noncontrolling interests		2,933
Distributions to noncontrolling interests		(916	)
Balance at December 31, 2020		55,315
Acquisition of redeemable noncontrolling interests		6,734
Net income attributable to noncontrolling interests		4,927
Distributions to noncontrolling interests		(1,588	)
Balance at December 31, 2021	$	65,388

Variable Interest Entities (Tables)

12 Months Ended

Dec. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Consolidated VIEs Assets and Liabilities

The consolidated VIEs assets and liabilities in the Company’s consolidated balance sheets are shown below (in thousands):

	December 31,
	2021		2020
Cash and cash equivalents	$	26,360	$	15,151
Accounts receivable, net		20,144		18,507
Other current assets		1,304		1,461
Total current assets		47,808		35,119
Property and equipment, net		220,793		175,103
Goodwill		34,945		34,945
Intangible assets, net		10,490		9,581
Operating lease right-of-use assets		6,603		6,909
Total assets	$	320,639	$	261,657


Accounts payable	$	3,690	$	4,143
Accrued salaries and benefits		5,656		4,357
Current portion of operating lease liabilities		197		164
Other accrued liabilities		6,818		8,366
Total current liabilities		16,361		17,030
Operating lease liabilities		6,666		6,863
Other liabilities		1,083		2,166
Total liabilities	$	24,110	$	26,059

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

Accumulated Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2019	$	(504,528	)	$	43,966		$	(1,815	)	$	(462,377	)
Foreign currency translation gain (loss)		69,895			—			(84	)		69,811
Loss on derivative instruments, net of tax of $(3.6) million		—			(19,008	)		—			(19,008	)
Pension liability adjustment, net of tax of $(0.6) million		—			—			(3,310	)		(3,310	)
Balance at December 31, 2019		(434,633	)		24,958			(5,209	)		(414,884	)
Foreign currency translation gain (loss)		61,532			—			(285	)		61,247
Loss on derivative instruments, net of tax of $(3.9) million		—			(11,272	)		—			(11,272	)
Pension liability adjustment, net of tax of $(0.8) million		—			—			(6,456	)		(6,456	)
Balance at December 31, 2020		(373,101	)		13,686			(11,950	)		(371,365	)
Foreign currency translation (loss) gain		(4,293	)		—			33			(4,260	)
Gain on derivative instruments, net of tax of $0.1 million		—			19			—			19
U.K. Sale		377,394			(13,705	)		11,917			375,606
Balance at December 31, 2021	$	—		$	—		$	—		$	—

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

Stock option activity during 2019, 2020 and 2021 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2019		1,199,540		$	44.64		7.26	$	2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068			39.40		7.57		1,650
Options granted		507,600			33.13		9.18		157
Options exercised		(68,700	)		29.15	N/A			854
Options cancelled		(288,662	)		39.67	N/A		N/A
Options outstanding at December 31, 2020		1,510,306			37.56		7.35		1,414
Options granted		324,320			57.53		9.31		851
Options exercised		(558,322	)		39.45	N/A			11,118
Options cancelled		(170,235	)		40.08	N/A		N/A
Options outstanding at December 31, 2021		1,106,069		$	42.07		7.49	$	19,988
Options exercisable at December 31, 2020		596,606		$	45.37		5.55	$	543
Options exercisable at December 31, 2021		324,409		$	43.24		5.48	$	5,575

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2021, 2020 and 2019:

	Year Ended December 31,
	2021			2020			2019
Weighted average grant-date fair value of options	$	20.64		$	12.37		$	17.59
Risk-free interest rate		0.9	%		1.6	%		2.4	%
Expected volatility		40	%		41	%		38	%
Expected life (in years)		5.0			5.0			5.0

Restricted Stock Activity

Restricted stock activity during 2019, 2020 and 2021 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14
Granted		637,312			25.82
Cancelled		(129,683	)		34.56
Vested		(289,769	)		35.88
Unvested at December 31, 2020		1,022,996		$	28.41
Granted		352,430			58.32
Cancelled		(82,751	)		39.63
Vested		(366,048	)		30.81
Unvested at December 31, 2021		926,627		$	37.84

Restricted Stock Unit Activity

Restricted stock unit activity during 2019, 2020 and 2021 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89
Granted		583,680			10.60
Performance adjustment		117,772			13.50
Cancelled		(63,056	)		43.35
Vested		(12,691	)		42.09
Unvested at December 31, 2020		1,073,062		$	20.15
Granted		149,416			61.52
Performance adjustment		465,993			25.49
Cancelled		—			—
Vested		(184,051	)		42.30
Unvested at December 31, 2021		1,504,420		$	23.20

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Components of Provision for Income Taxes

Provision for income taxes consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2021			2020			2019
Current:
Federal	$	48,292		$	(18,215	)	$	18,954
State		6,715			4,981			3,440
Foreign		778			732			1,602
Total current		55,785			(12,502	)		23,996
Deferred:
Federal		13,339			46,442			(1,572	)
State		(1,892	)		564			2,509
Foreign		325			6,102			152
Total deferred provision		11,772			53,108			1,089
Provision for income taxes	$	67,557		$	40,606		$	25,085

Effective Income Tax Rate

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2021			2020			2019
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		21.0	%
Impact of foreign operations		1.7			(0.5	)		1.1
Effects of statutory rate change		—			3.2			—
State income taxes, net of federal tax effect		3.9			5.1			5.8
Permanent differences		1.7			1.5			3.3
Change in valuation allowance		(2.8	)		127.4			0.6
Unrecognized tax benefit release		(0.9	)		(0.4	)		0.5
Federal tax credits		(0.8	)		(1.0	)		(2.2	)
Basis recognition related to foreign divestiture		—			(129.9	)		—
CARES Act impacts to net operating losses		—			(4.5	)		—
Other		0.7			0.2			1.9
Effective income tax rate		24.5	%		22.1	%		32.0	%

Summary of Domestic and Foreign Components of Income from Continuing Operations before Income Taxes

The domestic and foreign components of income from continuing operations before income taxes for continuing operations are as follows (in thousands):

	Year Ended December 31,
	2021		2020		2019
Foreign	$	5,596	$	9,904	$	6,070
Domestic		270,164		173,893		72,325
Income from continuing operations before income taxes	$	275,760	$	183,797	$	78,395

Deferred Tax Assets and Liabilities

	December 31,
	2021			2020
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	9,354		$	7,486
Capital loss carryovers (a)		215,367			239,269
Bad debt allowance		1,083			1,243
Accrued compensation and severance		18,241			20,889
Insurance reserves		18,847			18,497
Leases		896			846
Accrued expenses		5,768			11,817
Interest carryforwards		3,396			3,374
Lease right-of-use liabilities		26,154			24,402
Other assets		8,066			13,251
Total gross deferred tax assets		307,172			341,074
Less: valuation allowance		(217,325	)		(241,225	)
Deferred tax assets		89,847			99,849
Deferred tax liabilities:
Fixed asset basis difference		(2,456	)		(5,553	)
Prepaid items		(2,882	)		(2,960	)
Intangible assets		(126,446	)		(115,196	)
Lease right-of-use assets		(24,660	)		(22,948	)
Investment in foreign subsidiary		(4,691	)		—
Total deferred tax liabilities		(161,135	)		(146,657	)
Total net deferred tax liability	$	(71,288	)	$	(46,808	)

(a)	The presentation of the December 31, 2020 deferred tax liability attributable to the U.K. divestiture has been adjusted to reflect the final outcome of the sale.

Unrecognized Income Tax Benefits Net of Federal Benefit

A reconciliation of the beginning and ending amount of unrecognized income tax benefits, exclusive of any interest and penalties, net of the federal benefit, is as follows (in thousands):

	2021			2020
Balance at January 1	$	2,060		$	2,441
Additions based on tax positions related to the current year		—			—
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(2,060	)		(381	)
Balance at December 31	$	—		$	2,060

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Credit Facilities and Contingent Consideration Liabilities

	Carrying Amount				Fair Value
	December 31,				December 31,
	2021		2020		2021		2020
New Credit Facility	$	584,418	$	—	$	584,418	$	—
Prior Credit Facility	$	—	$	1,175,437	$	—	$	1,175,437
5.625% Senior Notes due 2023	$	—	$	646,344	$	—	$	647,960
6.500% Senior Notes due 2024	$	—	$	385,636	$	—	$	393,850
5.500% Senior Notes due 2028	$	443,894	$	443,139	$	466,577	$	475,931
5.000% Senior Notes due 2029	$	468,907	$	468,245	$	481,802	$	499,852
Other long-term debt	$	—	$	3,625	$	—	$	3,625
Derivative instrument liabilities	$	—	$	84,584	$	—	$	84,584

Financial Information Combined Wholly-Owned Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summarized Balance Sheet

Summarized balance sheet information (in thousands):

	December 31,
	2021		2020
Current assets	$	422,113	$	654,735
Property and equipment, net		1,525,569		1,421,875
Goodwill		2,086,978		1,992,305
Total noncurrent assets		3,893,087		3,640,809

Current liabilities		385,044		626,419
Long-term debt		1,460,046		2,786,125
Total noncurrent liabilities		1,752,271		3,045,981
Redeemable noncontrolling interests		—		—
Total equity		2,177,885		623,144

Summarized Statements of Income (Loss)

Summarized operating results information (in thousands):

	For the Year Ended December 31, 2021
Revenue	$	2,132,637
Income from continuing operations before income taxes		246,473
Net income		184,785
Net income attributable to Acadia Healthcare Company, Inc.		184,785

Description of Business and Basis of Presentation - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($) Facility Bed State	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Accounting Policies [Abstract]
Number of facilities \| Facility	238
Number of beds \| Bed	10,500
Number of operating states \| State	40
General and administrative expenses \| $	$ 108.2	$ 97.8	$ 90.4

Summary of Significant Accounting Policies - Additional Information (Detail)			1 Months Ended	3 Months Ended			12 Months Ended
	Oct. 01, 2021 USD ($) Segment	Jan. 19, 2021 USD ($)	Aug. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) Facility	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($) Facility Bed	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Significant Accounting Policies [Line Items]
Maximum professional liability aggregate policy limit							$ 60,000,000.0
Professional and general liability reserve				$ 87,800,000			87,800,000	$ 77,500,000
Professional and general liability reserve current				11,900,000			11,900,000	9,700,000
Professional and general liability reserve noncurrent				75,900,000			75,900,000	67,800,000
Insurance receivable				37,900,000			37,900,000	27,200,000
Insurance receivable - current portion				10,807,000			10,807,000	6,792,000
Insurance receivable noncurrent				27,100,000			27,100,000	20,400,000
Workers compensation insurance claims deductible per accident							500,000
Reserve for workers compensation liability							23,600,000	23,000,000.0
Accrued salaries and benefits				12,000,000.0			12,000,000.0	12,000,000.0
Other long-term liabilities				11,600,000			11,600,000	11,000,000.0
Depreciation expense							106,700,000	95,300,000	$ 87,900,000
Number of beds, replacement facility \| Bed						260
Non-cash property impairment charge relating to existing facility					$ 1,100,000	$ 23,200,000	24,300,000	4,200,000
Impairment of long-lived assets	$ 0			$ 0				4,200,000	$ 27,200,000
Number of reporting units \| Segment	1
Number of outpatient \| Facility				1		1
Proceeds from U.K. Sale				$ 1,500,000		$ 4,300,000	1,511,020,000
Goodwill write down				700,000		1,800,000	$ 2,449,000
Intangible assets for the disposition				$ 100,000		$ 200,000
Non-cash impairment charge related to indefinite-lived assets								600,000
ASU 2017-12 [Member]
Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]				true			true
Change in Accounting Principle, Accounting Standards Update, Adoption Date				Jan. 01, 2019			Jan. 01, 2019
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]				true			true
U.S. Facilities [Member]
Significant Accounting Policies [Line Items]
Goodwill impairment loss							$ 0
Discontinued Operations [Member] \| U.K. Facilities [Member]
Significant Accounting Policies [Line Items]
Proceeds from U.K. Sale		$ 1,525,000,000
Goodwill impairment loss							356,200,000	356,200,000
Closed Facilities [Member] \| U.S. Facilities [Member]
Significant Accounting Policies [Line Items]
Non-cash impairment charge related to indefinite-lived assets								$ 600,000
Maximum [Member]
Significant Accounting Policies [Line Items]
Maximum self insured professional liability limit per claim			$ 3,000,000				$ 10,000,000.0
Maximum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life							50 years
Maximum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life							7 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Maximum professional liability retention limit							$ 3,000,000
Minimum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life							10 years
Minimum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life							3 years

Summary of Significant Accounting Policies - Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 22,292	$ 19,480
Assets held for sale	15,808
Workers’ compensation deposits – current portion	12,000	12,000
Insurance receivable - current portion	10,807	6,792
Other receivables	10,786	10,025
Inventory	4,786	4,851
Income taxes receivable	1,523	897
Cost report receivable		5,818
Other	1,884	1,469
Other current assets	$ 79,886	$ 61,332

Summary of Significant Accounting Policies - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts Payable And Accrued Liabilities Current [Abstract]
Unearned income	$ 30,371	$ 35,946
Accrued expenses	26,791	28,452
Accrued interest	17,418	40,479
Government relief funds	12,718	5,495
Insurance liability – current portion	11,923	9,700
Accrued property taxes	8,375	6,763
Cost report payable	6,487
Income taxes payable	5,540	16,345
Finance lease liabilities	$ 990	$ 32,188
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other accrued liabilities	Other accrued liabilities
Other	$ 5,886	$ 3,085
Other accrued liabilities	$ 126,499	$ 178,453

U.K. Sale - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended			12 Months Ended
	Jan. 19, 2021	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale of business		$ 1,500	$ 4,300		$ 1,511,020
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross proceeds from sale of business	$ 1,525,000
Settlement of existing foreign currency hedging liabilities	85,000
Net proceeds from sale of business	$ 1,425,000
Cash from the balance sheet to reduce debt, amount				$ 1,640,000
Loss on sale				$ 14,300		$ 867,300
Goodwill impairment loss					$ 356,200	356,200
Cash paid for capital expenditures						$ 48,400	$ 59,600

U.K. Sale - Result of Operation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) income from discontinued operations	$ (12,641)	$ (812,390)	$ 56,812
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	62,520	1,119,768	1,099,081
Salaries, wages and benefits	35,937	632,134	609,823
Professional fees	6,815	127,291	122,532
Supplies	2,217	38,285	37,527
Rents and leases	2,509	47,748	46,743
Other operating expenses	6,682	113,534	115,897
Depreciation and amortization		74,935	76,121
Interest expense, net	10	(417)	(231)
Loss on sale	13,490	867,324
Loss on impairment		20,239	27,169
Transaction-related expenses	6,265	8,719	5,907
Total expenses	73,925	1,929,792	1,041,488
(Loss) income from discontinued operations before income taxes	(11,405)	(810,024)	57,593
Provision for income taxes	1,236	2,366	781
(Loss) income from discontinued operations	$ (12,641)	$ (812,390)	$ 56,812

U.K. Sale - Major Classes of Assets and Liabilities (Detail) $ in Thousands	Dec. 31, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets of discontinued operations	$ 1,809,815
Current liabilities:
Current liabilities of discontinued operations	660,027
Discontinued Operations [Member] \| U.K. Sales [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	75,051
Accounts receivable, net	52,196
Other current assets	13,361
Current assets of discontinued operations	140,608
Property and equipment, net	1,297,923
Intangible assets, net	22,289
Operating lease right-of-use assets	341,289
Other assets	7,706
Total assets of discontinued operations	1,809,815
Current liabilities:
Accounts payable	44,929
Current portion of operating lease liabilities	11,141
Other current liabilities	136,895
Current liabilities of discontinued operations	192,965
Operating lease liabilities	387,607
Deferred tax liabilities	57,230
Other liabilities	22,225
Total liabilities of discontinued operations	$ 660,027

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 30, 2020	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Accounts receivable, net			$ 2,448	$ 15,340	$ (18,714)
Cost report payable			6,487
Cost report receivables				5,818
Net adjustments to estimated cost report settlements resulted in (decreases) increases to revenue			(5,400)	(1,300)	400
Costs of providing charity care services			3,800	4,400	$ 4,300
CARES Act [Member] \| Medicare [Member]
Disaggregation of Revenue [Line Items]
Repayment of advanced payments		$ 25,000
Repayment of advanced payments period	2022
CARES Act [Member] \| CMS' Accelerated and Advance Payment Program [Member] \| Medicare [Member]
Disaggregation of Revenue [Line Items]
Amount of advance payment received	$ 45,000
Repayment of advanced payments			25,000
Repayment of advanced payments description	In April 2020, the Company received approximately $45 million from CMS’ Accelerated and Advance Payment Program for Medicare providers. The Company repaid approximately $25 million of the $45 million of advance payments during 2021 via recoupment from the Company’s new Medicare claims and will continue to repay the remaining balance throughout 2022.
Repayment of advanced payments period	2022
CARES Act [Member] \| CMS' Accelerated and Advance Payment Program [Member] \| Medicare [Member] \| Other Accrued Liabilities [Member]
Disaggregation of Revenue [Line Items]
Contract liabilities			30,400	35,900
CARES Act [Member] \| CMS' Accelerated and Advance Payment Program [Member] \| Medicare [Member] \| Other Liabilities [Member]
Disaggregation of Revenue [Line Items]
Contract liabilities				11,300
Accounting Standards Update 2014-09
Disaggregation of Revenue [Line Items]
Accounts receivable, net			$ 49,700	$ 62,100

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 2,314,394	$ 2,089,929	$ 2,008,381
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	2,314,394	2,089,929	2,008,381
U.S. Facilities [Member] \| Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	1,126,872	984,609	912,097
U.S. Facilities [Member] \| Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	896,564	802,022	788,232
U.S. Facilities [Member] \| Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	283,169	281,158	286,959
U.S. Facilities [Member] \| Other [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 7,789	$ 22,140	$ 21,093

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue - Schedule of Revenue and Percentage Generated by Each Payor Type in U.S Facilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 2,314,394	$ 2,089,929	$ 2,008,381
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 2,314,394	$ 2,089,929	$ 2,008,381
Revenue, Percentage	100.00%	100.00%	100.00%
U.S. Facilities [Member] \| Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 684,292	$ 596,698	$ 565,350
Revenue, Percentage	29.60%	28.50%	28.20%
U.S. Facilities [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 364,598	$ 330,070	$ 294,691
Revenue, Percentage	15.80%	15.80%	14.70%
U.S. Facilities [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 1,147,884	$ 1,037,852	$ 1,007,102
Revenue, Percentage	49.60%	49.70%	50.10%
U.S. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 93,425	$ 98,302	$ 118,716
Revenue, Percentage	4.00%	4.70%	5.90%
U.S. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 24,195	$ 27,007	$ 22,522
Revenue, Percentage	1.00%	1.30%	1.10%

- Definition

+ References

+ Details

Revenue - Summary of the Activity in Unearned Revenue in U.S. Facilities (Detail) - U.S. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 47,196
Payments received	11,739
Revenue recognized	(3,463)
Ending Balance	30,371
Medicare [Member]
Disaggregation of Revenue [Line Items]
Medicare advance repayments	$ (25,101)

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 203,276	$ 140,258	$ 52,111
(Loss) income from discontinued operations	(12,641)	(812,390)	56,812
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 190,635	$ (672,132)	$ 108,923
Denominator:
Basic	88,769	87,875	87,612
Effects of dilutive instruments	2,024	720	204
Shares used in computing diluted earnings per common share	90,793	88,595	87,816
Basic earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	$ 2.29	$ 1.60	$ 0.59
(Loss) income from discontinued operations	(0.14)	(9.25)	0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	2.15	(7.65)	1.24
Diluted earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders:
Income from continuing operations attributable to Acadia Healthcare Company, Inc.	2.24	1.58	0.59
(Loss) income from discontinued operations	(0.14)	(9.17)	0.65
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ 2.10	$ (7.59)	$ 1.24

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	0.3	1.9	2.2

Acquisitions - Additional Information (Detail) $ in Millions	Dec. 31, 2021 USD ($) Bed Hospital Location	Apr. 01, 2019 USD ($) Bed	Feb. 15, 2019 USD ($) Bed Center
Business Acquisition [Line Items]
Number of beds \| Bed	10,500
CenterPointe Behavioral Health System, LLC [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration	$ 139.0
Revolving Facility	$ 70.0
Number of acute inpatient hospitals \| Hospital	4
Number of beds \| Bed	306
Number of outpatient locations \| Location	10
Bradford Recovery Center [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration		$ 4.5
Number of beds \| Bed		46
Whittier Pavilion [Member] \| Massachusetts [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration			$ 17.9
Number of beds \| Bed			71
Mission Treatment [Member] \| California, Nevada, Arizona and Oklahoma [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration			$ 22.5
Number of comprehensive treatment centers operates \| Center			9

Acquisitions - Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill	$ 2,199,937	$ 2,105,264	$ 2,085,104
CenterPointe Behavioral Health System, LLC [Member]
Business Acquisition [Line Items]
Cash	5,640
Accounts receivable, net	10,230
Other current assets	2,087
Property and equipment	35,670
Goodwill	97,122
Intangible assets	825
Deferred tax assets	1,573
Operating lease right-of-use assets	28,858
Total assets acquired	182,005
Accounts payable	3,820
Accrued salaries and benefits	3,585
Current portion of operating lease liabilities	2,582
Other accrued liabilities	1,088
Operating lease liabilities	26,275
Total liabilities assumed	37,350
Net assets acquired	$ 144,655

Acquisitions - Summary of Changes in Goodwill (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Combinations [Abstract]
Goodwill balance			$ 2,105,264	$ 2,085,104
Increase from acquisitions			97,122
Increase from contribution of redeemable noncontrolling interests				20,200
Adjustments related to 2019 acquisitions				(40)
2021 dispositions	$ (700)	$ (1,800)	(2,449)
Goodwill balance	$ 2,199,937		$ 2,199,937	$ 2,105,264

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Combinations [Abstract]
Legal, accounting and other acquisition-related costs	$ 8,315	$ 8,252	$ 3,030
Termination, restructuring and strategic review costs	4,463	3,468	12,598
Management transition costs			5,529
Transaction-related expenses	$ 12,778	$ 11,720	$ 21,157

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,312,285	$ 2,072,539
Less: accumulated depreciation	(541,126)	(449,643)
Property and equipment, net	1,771,159	1,622,896
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	154,376	144,221
Building and Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,683,560	1,490,149
Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	253,100	220,690
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 221,249	$ 217,479

Property and Equipment - Additional information (Detail) $ in Millions	3 Months Ended		12 Months Ended
	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($) Bed	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Property Plant And Equipment [Line Items]
Loss on impairment	$ 1.1	$ 23.2	$ 24.3	$ 4.2
Number of beds, replacement facility \| Bed		260
Other Assets [Member]
Property Plant And Equipment [Line Items]
Assets held for sale			$ 15.8	$ 17.1

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	$ 70,145	$ 68,535
Total	71,276	69,666
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(1,131)	(1,131)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	11,600	11,873
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	40,435	39,526
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	18,110	17,136
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,131	1,131
Intangible assets subject to amortization, Accumulated Amortization	$ (1,131)	$ (1,131)

Other Intangible Assets - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($) Facility	Jun. 30, 2021 USD ($) Facility	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Non-cash impairment charge related to indefinite-lived assets				$ 600
Number of outpatient \| Facility	1	1
Gross proceeds from sale of business	$ 1,500	$ 4,300	$ 1,511,020
Goodwill write down	700	1,800	$ 2,449
Intangible assets for the disposition	$ 100	$ 200

Leases - Additional Information (Detail)	12 Months Ended
Leases - Additional Information (Detail)	Dec. 31, 2021
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	5 years
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	30 years
Copiers and Equipment [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	1 year
Copiers and Equipment [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	3 years

Leases - Schedule of Leases on Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net	Property and equipment, net
Operating lease right-of-use assets	$ 133,761	$ 96,937
Total	142,388	131,558
Finance lease liabilities	$ 990	$ 32,188
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other accrued liabilities	Other accrued liabilities
Operating lease liabilities	$ 23,348	$ 18,916
Finance lease liabilities	$ 10,807
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Operating lease liabilities	$ 116,841	$ 84,029
Total	151,986	145,877
Property and Equipment, Net [Member]
Lessee Lease Description [Line Items]
Finance lease right-of-use assets	8,627	34,621
Operating Lease Right-of-use Assets [Member]
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	133,761	96,937
Other Accrued Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	990	32,188
Current Portion of Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	23,348	18,916
Other Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	10,807	10,744
Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	$ 116,841	$ 84,029

Leases - Schedule of Weighted-average Remaining Lease Terms and Discount Rates (Detail)	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Finance lease, weighted average remaining lease term (years)	22 years 10 months 24 days	6 years 8 months 12 days
Operating lease, weighted average remaining term (years)	9 years 1 month 6 days	8 years 6 months
Finance lease, weighted average discount rate percent	5.10%	5.90%
Operating lease, weighted average discount rate percent	5.10%	6.50%

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finance lease costs:
Depreciation of leased assets	$ 378	$ 868
Interest of lease liabilities	2,174	3,214
Total finance lease costs	2,552	4,082
Operating lease costs	28,233	27,050
Variable lease costs	2,488	2,501
Short term lease costs	3,257	3,558
Other lease costs	4,541	4,253
Total rents and leases	38,519	37,362	$ 35,486
Total lease costs	$ 41,071	$ 41,444

Leases - Schedule of Undiscounted Cash Flows for Finance and Operating Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finance Leases
2021	$ 990
2022	990
2023	1,007
2024	1,089
2025	1,089
Thereafter	22,911
Total minimum lease payments	28,076
Less: amount of lease payments representing interest	16,279
Present value of future minimum lease payments	11,797
Less: Current portion of lease liabilities	990	$ 32,188
Noncurrent lease liabilities	10,807
Operating Leases
2021	29,973
2022	26,471
2023	23,110
2024	19,730
2025	14,500
Thereafter	68,427
Total minimum lease payments	182,211
Less: amount of lease payments representing interest	42,022
Present value of future minimum lease payments	140,189
Current portion of operating lease liabilities	23,348	18,916
Operating lease liabilities	$ 116,841	$ 84,029

Leases - Schedule of Supplemental Data (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 27,508	$ 26,810
Operating cash flows for finance leases	2,174	3,214
Financing cash flows for finance leases	31,136	551
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 63,279	$ 21,285

The CARES Act - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended				12 Months Ended
	Apr. 24, 2020	Apr. 30, 2021	Aug. 31, 2020	Apr. 30, 2020	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017
CARES Act [Line Items]
Income from relief fund									$ 17,900	$ 32,819
Expected repay of payroll tax deferrals						$ 39,000
Received benefit in form of refunds and lower future tax payments									51,600	51,600
Received benefit related to interest expense									22,800	22,800
Received benefit related to qualified improvement property legislation									20,500	20,500
Expected permanent cash benefit due to loss									$ 8,300	$ 8,300
Effective income tax rate reconciliation at federal statutory income tax rate									21.00%	21.00%	21.00%	35.00%
CARES Act [Member]
CARES Act [Line Items]
Offer of eligible relief amount								$ 100,000,000
Additional offer of eligible relief amount	$ 75,000,000
Remaining unrecognized funds					$ 6,300				$ 6,300
Cash benefit relating to delay of payment of social security payroll taxes									$ 39,000
Net operating loss carryforwards and carrybacks offset percentage of taxable income									100.00%
Net operating loss carried back period									5 years
CARES Act [Member] \| Medicare [Member]
CARES Act [Line Items]
Repayment of advanced payments						$ 25,000
Percentage of increase in medicare reimbursement rate								2.00%
Repayment of advanced payments period				2022
CARES Act [Member] \| Public Health and Social Services Emergency Fund [Member]
CARES Act [Line Items]
Receipt of CARES Act of 2020 aid amount								$ 19,700	$ 34,900
Receipt of additional CARES Act of 2020 aid amount		$ 24,200	$ 12,800
Income from relief fund					$ 17,900
Other income							$ 32,800	18,100
CARES Act [Member] \| CMS' Accelerated and Advance Payment Program [Member] \| Medicare [Member]
CARES Act [Line Items]
Amount of advance payment received								$ 45,000

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021	Mar. 17, 2021	Dec. 31, 2020	Nov. 13, 2020	Sep. 21, 2015
Debt Instrument [Line Items]
Other long-term debt				$ 3,625
Less: unamortized debt issuance costs, discount and premium	$ (14,811)			(30,802)
Long-term debt	1,497,220			3,122,426
Less: current portion	(18,594)			(153,478)
Long-term debt	1,478,626			2,968,948
Term Loan A [Member]
Debt Instrument [Line Items]
Revolving Facility					$ 352,400
Prior Credit Facility [Member] \| Senior Secured Term A Loan [Member]
Debt Instrument [Line Items]
Revolving Facility				311,733
Prior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Revolving Facility				872,870
New Credit Facility [Member] \| Term Loan A [Member]
Debt Instrument [Line Items]
Revolving Facility	417,031		$ 425,000
New Credit Facility [Member] \| Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Revolving Facility	170,000	$ 160,000	$ 600,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes				650,000		$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes				390,000
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Senior Notes	450,000			450,000
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 475,000			$ 475,000

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Oct. 14, 2020	Jun. 24, 2020	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%				5.625%	5.625%
Senior notes maturity year	2023	2023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%			6.50%
Senior notes maturity year	2024	2024
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
Senior notes maturity year	2028	2028
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.00%	5.00%	5.00%
Senior notes maturity year	2029	2029

Long-Term Debt (New Credit Facility) - Additional Information (Detail) - USD ($)		3 Months Ended		12 Months Ended
	Mar. 17, 2021	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 13, 2020
Debt Instrument [Line Items]
Repayments of revolving facility				$ 330,000,000	$ 100,000,000	$ 76,573,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount							$ 352,400,000
New Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement	Mar. 17, 2021
Repayments of revolving facility			$ 60,000,000.0
Proceeds from revolving facility		$ 70,000,000.0
Term loan remaining balance due date				Mar. 17, 2026
Maximum incremental debt amount		$ 480,000,000.0		$ 480,000,000.0
Incremental debt amount maximum percentage of consolidated EBITDA		100.00%		100.00%
Consolidated senior secured net leverage ratio		350.00%		350.00%
Maximum consolidated net leverage ratio		500.00%		500.00%
Minimum interest coverage ratio		300.00%		300.00%
New Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				1.75%
New Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate				0.75%
New Credit Facility [Member] \| December 31, 2021 to March 31, 2022 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				$ 2,700,000
New Credit Facility [Member] \| June 30, 2022 to March 31, 2024 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				5,300,000
New Credit Facility [Member] \| June 30, 2024 to March 31, 2025 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				8,000,000.0
New Credit Facility [Member] \| June 30, 2025 to December 31, 2025 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				10,600,000
New Credit Facility [Member] \| Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 600,000,000.0	$ 170,000,000	$ 160,000,000.0	170,000,000
Debt instrument maturity date	Mar. 17, 2026
Amount available under revolving line of credit		426,900,000		$ 426,900,000
Unused fee payable percentage				0.25%
New Credit Facility [Member] \| Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 425,000,000.0	417,031,000		$ 417,031,000
Debt instrument maturity date	Mar. 17, 2026
New Credit Facility [Member] \| Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 20,000,000.0
New Credit Facility [Member] \| Swingline Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount	$ 20,000,000.0
New Credit Facility [Member] \| Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount		$ 3,100,000		$ 3,100,000
Amended and Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Agreement termination date	Mar. 17, 2021

Long-Term Debt (Prior Credit Facility) - Additional Information (Detail) - USD ($) $ in Thousands										3 Months Ended	12 Months Ended
	Jan. 19, 2021	Jan. 05, 2021	Nov. 13, 2020	Apr. 21, 2020	Feb. 27, 2019	Feb. 06, 2019	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 29, 2018
Debt Instrument [Line Items]
Debt extinguishment costs											$ (24,650)	$ (7,233)
Tranche B-4 Facilities [Member]
Debt Instrument [Line Items]
Repayments of credit facility	$ 767,900	$ 105,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount			$ 352,400
Repayments of credit facility	$ 311,700
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement								Dec. 31, 2012	Apr. 01, 2011
Debt instrument maturity date							Nov. 30, 2021
Debt extinguishment costs										$ 10,900
Prior Credit Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Debt instrument maturity date			Nov. 30, 2022
Debt extinguishment costs			$ 1,000
Prior Credit Facility [Member] \| Revolving Line of Credit [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Line of credit			459,000										$ 500,000
Prior Credit Facility [Member] \| Term Loan A- Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Line of credit outstanding principal amount			$ 318,900
Eleventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement						Feb. 06, 2019
Twelfth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement					Feb. 27, 2019
Thirteenth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement				Apr. 21, 2020

Long-Term Debt (5.500% Senior Notes due 2028) - Additional Information (Detail) - 5.500% Senior Notes due 2028 [Member] - USD ($)		12 Months Ended
	Jun. 24, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Issued Senior Notes	$ 450,000,000.0
Debt instrument interest rate	5.50%	5.50%	5.50%
Debt instrument maturity date	Jul. 01, 2028
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021

Long-Term Debt (5.000% Senior Notes due 2029) - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Oct. 14, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt extinguishment costs		$ (24,650)	$ (7,233)
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Issued Senior Notes	$ 475,000
Debt instrument interest rate	5.00%	5.00%	5.00%
Debt instrument maturity date	Apr. 15, 2029
Interest on the notes		payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021
Tranche B-3 Facility [Member]
Debt Instrument [Line Items]
Debt extinguishment charge	$ 453,300
Debt extinguishment costs	$ 2,900

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000.0	$ 375,000,000.0
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes		$ 650,000,000	$ 650,000,000.0
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	payable semi-annually in arrears on February 15 and August 15 of each year
Term loan remaining balance due date	Mar. 17, 2021

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		12 Months Ended
	Feb. 16, 2016	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000.0
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016
Term loan remaining balance due date		Mar. 01, 2021

Long-Term Debt (Redemption of 5.265% Senior Notes and 6.500% Senior Notes) - Additional Information (Detail) - USD ($) $ in Thousands				12 Months Ended
	Mar. 17, 2021	Mar. 01, 2021	Jan. 29, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt extinguishment costs				$ (24,650)	$ (7,233)
Redemption of 5.265% Senior Notes [Member]
Debt Instrument [Line Items]
Senior Notes			$ 650,000
Debt instrument interest rate			5.625%
Debt extinguishment costs	$ 3,300
Redemption of 6.500% Senior Notes [Member]
Debt Instrument [Line Items]
Senior Notes			$ 390,000
Debt instrument interest rate			6.50%
Debt extinguishment costs		$ 10,500
Cash paid for breakage costs		6,300
Write off of deferred financing costs		$ 4,200
Redemption of 5.265% Senior Notes and 6.500% Senior Notes [Member]
Debt Instrument [Line Items]
Term loan remaining balance due date			Jan. 29, 2021

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		12 Months Ended
	Mar. 12, 2013	Dec. 31, 2021
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000.0
Debt instrument interest rate	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		payable semi-annually in arrears on March 15 and September 15 of each year
Term loan remaining balance due date		Jun. 24, 2020

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		12 Months Ended
	Jul. 01, 2014	Dec. 31, 2021
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000.0
Debt instrument interest rate	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year
Term loan remaining balance due date		Jun. 24, 2020

Long-Term Debt (Redemption of 6.125% Senior Notes and 5.125% Senior Notes) - Additional Information (Detail) - USD ($) $ in Millions		12 Months Ended
	Jun. 10, 2020	Dec. 31, 2021	Dec. 31, 2020	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		6.125%			6.125%
Term loan remaining balance due date		Jun. 24, 2020
Debt instrument, redemption price percentage of principal amount	100.00%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		5.125%		5.125%
Term loan remaining balance due date		Jun. 24, 2020
Debt instrument, redemption price percentage of principal amount	100.00%
6.125% Senior Notes Due 2021 and 5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt extinguishment charge			$ 3.3

Long-Term Debt (Other Long-term Debt) - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Debt Disclosure [Abstract]
Repayments of other long-term debt	$ 3.3

Long-Term Debt (Debt Issuance Costs) - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Debt issuance costs	$ 14.8	$ 29.8
Accumulated amortization	2.4	56.0
Amortization expenses reported as interest expense	$ 2.8	$ 9.8	$ 9.7

Long-Term Debt (Other) - Summary of Aggregate Maturities of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Debt Disclosure [Abstract]
2022	$ 18,594
2023	21,250
2024	29,219
2025	39,843
2026	478,125
Thereafter	925,000
Total	$ 1,512,031

Noncontrolling Interests - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	6
Non-Wholly Owned Subsidiaries [Member] \| Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Non-Wholly Owned Subsidiaries [Member] \| Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	86.00%

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Noncontrolling Interest [Abstract]
Beginning Balance	$ 55,315	$ 33,151
Acquisition of redeemable noncontrolling interests	6,734	20,147
Net income attributable to noncontrolling interests	4,927	2,933
Distributions to noncontrolling interests	(1,588)	(916)	$ (154)
Ending Balance	$ 65,388	$ 55,315	$ 33,151

Variable Interest Entities - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) Facility	Dec. 31, 2020 USD ($)
Variable Interest Entity [Line Items]
Consolidated assets	$ 4,768,078	$ 6,499,362
Consolidated liabilities	$ 2,185,201	4,544,591
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of facilities operated through non-wholly owned subsidiaries \| Facility	6
Consolidated assets	$ 320,639	261,657
Consolidated liabilities	$ 24,110	$ 26,059
Variable Interest Entity, Primary Beneficiary [Member] \| Minimum [Member]
Variable Interest Entity [Line Items]
Variable interest entity, ownership percentage	60.00%
Variable Interest Entity, Primary Beneficiary [Member] \| Maximum [Member]
Variable Interest Entity [Line Items]
Variable interest entity, ownership percentage	86.00%

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

+ Details

Variable Interest Entities - Schedule of Consolidated VIEs Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 133,813	$ 378,697
Accounts receivable, net	281,332	273,551
Other current assets	79,886	61,332
Total current assets	495,031	2,523,395
Property and equipment, net	1,771,159	1,622,896
Goodwill	2,199,937	2,105,264	$ 2,085,104
Intangible assets, net	70,145	68,535
Operating lease right-of-use assets	133,761	96,937
Total assets	4,768,078	6,499,362
Accounts payable	98,575	87,815
Accrued salaries and benefits	137,845	124,912
Current portion of operating lease liabilities	23,348	18,916
Other accrued liabilities	126,499	178,453
Total current liabilities	404,861	1,308,185
Operating lease liabilities	116,841	84,029
Other liabilities	110,505	133,412
Total liabilities	2,185,201	4,544,591
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	26,360	15,151
Accounts receivable, net	20,144	18,507
Other current assets	1,304	1,461
Total current assets	47,808	35,119
Property and equipment, net	220,793	175,103
Goodwill	34,945	34,945
Intangible assets, net	10,490	9,581
Operating lease right-of-use assets	6,603	6,909
Total assets	320,639	261,657
Accounts payable	3,690	4,143
Accrued salaries and benefits	5,656	4,357
Current portion of operating lease liabilities	197	164
Other accrued liabilities	6,818	8,366
Total current liabilities	16,361	17,030
Operating lease liabilities	6,666	6,863
Other liabilities	1,083	2,166
Total liabilities	$ 24,110	$ 26,059

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 1,899,456	$ 2,505,381	$ 2,333,307
Foreign currency translation gain (loss)	(4,260)	61,247	69,811
Gain (loss) on derivative instruments, net of tax of $0.1 million, $(3.9) million and $(3.6) million, respectively	19	(11,272)	(19,008)
Pension liability adjustment, net of tax of $0.0 million, $(0.8) million and $(0.6) million, respectively		(6,456)	(3,310)
U.K. Sale	375,606
Balance	2,517,489	1,899,456	2,505,381
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(373,101)	(434,633)	(504,528)
Foreign currency translation gain (loss)	(4,293)	61,532	69,895
U.K. Sale	377,394
Balance		(373,101)	(434,633)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	13,686	24,958	43,966
Gain (loss) on derivative instruments, net of tax of $0.1 million, $(3.9) million and $(3.6) million, respectively	19	(11,272)	(19,008)
U.K. Sale	(13,705)
Balance		13,686	24,958
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(11,950)	(5,209)	(1,815)
Foreign currency translation gain (loss)	33	(285)	(84)
Pension liability adjustment, net of tax of $0.0 million, $(0.8) million and $(0.6) million, respectively		(6,456)	(3,310)
U.K. Sale	11,917
Balance		(11,950)	(5,209)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (371,365)	(414,884)	(462,377)
Balance		$ (371,365)	$ (414,884)

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Gain (Loss) on derivative instruments, tax	$ 0.1	$ (3.9)	$ (3.6)
Pension liability adjustment, tax	$ 0.0	$ (0.8)	$ (0.6)

Equity - Additional Information (Detail) - shares	12 Months Ended
Equity - Additional Information (Detail) - shares	Dec. 31, 2021	Dec. 31, 2020
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000	10,000,000
Common stock, number of shares proposed to be issued	180,000,000	180,000,000
Common stock voting rights	one vote for each share
Maximum [Member]
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000
Common stock, number of shares proposed to be issued	180,000,000

Equity-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock		12,700,000
Equity incentive plan available for future grant	4,481,404
Annual increments in employee grants	25.00%
Stock options, contractual term	10 years
Equity-based compensation expense	$ 37,530,000	$ 22,504,000	$ 17,307,000
Unrecognized compensation expense related to unvested options	$ 39,800,000
Vesting period	1 year 2 months 12 days
Warrant outstanding	$ 0
Deferred income tax benefit	11,772,000	53,108,000	1,089,000
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 9,600,000	$ 5,500,000	$ 4,000,000.0
Restricted Stock Award [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Award [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Number of shares issuable at the end of the vesting period, percentage	0.00%
Restricted Stock Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Number of shares issuable at the end of the vesting period, percentage	200.00%

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance	1,510,306	1,360,068	1,199,540
Options granted	324,320	507,600	605,200
Options exercised	(558,322)	(68,700)	(55,671)
Options cancelled	(170,235)	(288,662)	(389,001)
Options outstanding, Ending balance	1,106,069	1,510,306	1,360,068	1,199,540
Options exercisable, Ending balance	324,409	596,606
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 37.56	$ 39.40	$ 44.64
Options granted, Weighted Average Exercise Price	57.53	33.13	28.50
Options exercised, Weighted Average Exercise Price	39.45	29.15	19.05
Options cancelled, Weighted Average Exercise Price	40.08	39.67	40.84
Options outstanding, Weighted Average Exercise Price, Ending balance	42.07	37.56	$ 39.40	$ 44.64
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 43.24	$ 45.37
Options outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 26 days	7 years 4 months 6 days	7 years 6 months 25 days	7 years 3 months 3 days
Options granted, Weighted Average Remaining Contractual Term	9 years 3 months 21 days	9 years 2 months 4 days	9 years 2 months 15 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	5 years 5 months 23 days	5 years 6 months 18 days
Options outstanding, Aggregate Intrinsic Value	$ 19,988	$ 1,414	$ 1,650	$ 2,717
Options granted, Aggregate Intrinsic Value	851	157	1,343
Options exercised, Aggregate Intrinsic Value	11,118	854	658
Options cancelled, Aggregate Intrinsic Value	0	0	$ 0
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 5,575	$ 543

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 20.64	$ 12.37	$ 17.59
Risk-free interest rate	0.90%	1.60%	2.40%
Expected volatility	40.00%	41.00%	38.00%
Expected life (in years)	5 years	5 years	5 years

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	1,022,996	805,136	805,057
Granted, Number of Shares	352,430	637,312	700,937
Cancelled, Number of Shares	(82,751)	(129,683)	(389,684)
Vested, Number of Shares	(366,048)	(289,769)	(311,174)
Unvested, Number of Shares/Units, Ending balance	926,627	1,022,996	805,136
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 28.41	$ 34.14	$ 42.40
Granted, Weighted Average Grant-Date Fair Value	58.32	25.82	28.77
Cancelled, Weighted Average Grant-Date Fair Value	39.63	34.56	33.50
Vested, Weighted Average Grant-Date Fair Value	30.81	35.88	44.23
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 37.84	$ 28.41	$ 34.14

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	1,073,062	447,357	484,111
Granted, Number of Units	149,416	583,680	234,408
Performance adjustment, Number of Units	465,993	117,772
Cancelled, Number of Units		(63,056)	(271,162)
Vested, Number of Units	(184,051)	(12,691)
Unvested, Number of Shares/Units, Ending balance	1,504,420	1,073,062	447,357
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 20.15	$ 38.89	$ 44.52
Granted, Weighted Average Grant-Date Fair Value	61.52	10.60	34.54
Performance adjustment, Weighted Average Grant-Date Fair Value	25.49	13.50
Cancelled, Weighted Average Grant-Date Fair Value		43.35	45.17
Vested, Weighted Average Grant-Date Fair Value	42.30	42.09
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 23.20	$ 20.15	$ 38.89

Income Taxes - Components of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 48,292	$ (18,215)	$ 18,954
State	6,715	4,981	3,440
Foreign	778	732	1,602
Total current	55,785	(12,502)	23,996
Deferred:
Federal	13,339	46,442	(1,572)
State	(1,892)	564	2,509
Foreign	325	6,102	152
Total deferred provision	11,772	53,108	1,089
Provision for income taxes	$ 67,557	$ 40,606	$ 25,085

Income Taxes - Effective Income Tax Rate (Detail)	12 Months Ended
Income Taxes - Effective Income Tax Rate (Detail)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S. federal statutory rate on income before income taxes	21.00%	21.00%	21.00%	35.00%
Impact of foreign operations	1.70%	(0.50%)	1.10%
Effects of statutory rate change		3.20%
State income taxes, net of federal tax effect	3.90%	5.10%	5.80%
Permanent differences	1.70%	1.50%	3.30%
Change in valuation allowance	(2.80%)	127.40%	0.60%
Unrecognized tax benefit release	(0.90%)	(0.40%)	0.50%
Federal tax credits	(0.80%)	(1.00%)	(2.20%)
Basis recognition related to foreign divestiture		(129.90%)
CARES Act impacts to net operating losses		(4.50%)
Other	0.70%	0.20%	1.90%
Effective income tax rate	24.50%	22.10%	32.00%

Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Income Tax Examination [Line Items]

Provision for income taxes

$ 67,557

$ 40,606

$ 25,085

Effective tax rates

24.50%

22.10%

32.00%

Deferred tax assets, investment in foreign subsidiaries

$ 239,100

Deferred tax assets, capital loss

^[1]

$ 215,367

239,269

Valuation allowance against deferred tax assets

217,325

241,225

Federal net operating loss carryforwards

Foreign net operating loss carryforwards

100

State net operating loss carry forwards

$ 227,300

170,000

Operating loss carryforwards expiration start year

2022

Operating loss carryforwards expiration end year

2035

Expiration of State tax credits

2030

State tax credits

$ 400

Income taxes receivable

24,600

900

Income tax payable included in other accrued liabilities

5,540

16,345

Unrecognized tax benefits

2,060

$ 2,441

Cumulative amounts of interest and penalties recognized

500

Unrecognized tax benefits would impact effective tax rate

$ 2,100

Foreign Tax Authority [Member]

Income Tax Examination [Line Items]

Period of examination by internal revenue service minimum

2017

Period of examination by internal revenue service maximum

2020

State and Local Jurisdiction [Member]

Income Tax Examination [Line Items]

Period of examination by internal revenue service minimum

2015

Period of examination by internal revenue service maximum

2020

Earliest Tax Year [Member] | Internal Revenue Service (IRS) [Member]

Income Tax Examination [Line Items]

Period of examination by internal revenue service

2018

Latest Tax Year [Member] | Internal Revenue Service (IRS) [Member]

Income Tax Examination [Line Items]

Period of examination by internal revenue service

2020

CARES Act [Member]

Income Tax Examination [Line Items]

Income tax payments in excess of accruals

$ 18,500

Other Assets [Member]

Income Tax Examination [Line Items]

Income taxes receivable

23,100

Other Current Assets [Member]

Income Tax Examination [Line Items]

Income taxes receivable

1,500

Other Liabilities [Member]

Income Tax Examination [Line Items]

Unrecognized tax benefits

$ 2,500

U.K. [Member]

Income Tax Examination [Line Items]

Provision for income taxes

7,500

Puerto Rico [Member]

Income Tax Examination [Line Items]

Deferred tax liabilities, undistributed foreign earnings

$ 4,600

[1]	The presentation of the December 31, 2020 deferred tax liability attributable to the U.K. divestiture has been adjusted to reflect the final outcome of the sale.

Income Taxes - Summary of Domestic and Foreign Components of Income from Continuing Operations before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Income from continuing operations before income taxes	$ 275,760	$ 183,797	$ 78,395
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Income from continuing operations before income taxes	5,596	9,904	6,070
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Income from continuing operations before income taxes	$ 270,164	$ 173,893	$ 72,325

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($)
$ in Thousands

Dec. 31, 2021

Dec. 31, 2020

Deferred tax assets:

Net operating losses and tax credit carryforwards - federal and state

$ 9,354

$ 7,486

Capital loss carryovers

^[1]

215,367

239,269

Bad debt allowance

1,083

1,243

Accrued compensation and severance

18,241

20,889

Insurance reserves

18,847

18,497

Leases

896

846

Accrued expenses

5,768

11,817

Interest carryforwards

3,396

3,374

Lease right-of-use liabilities

26,154

24,402

Other assets

8,066

13,251

Total gross deferred tax assets

307,172

341,074

Less: valuation allowance

(217,325)

(241,225)

Deferred tax assets

89,847

99,849

Deferred tax liabilities:

Fixed asset basis difference

(2,456)

(5,553)

Prepaid items

(2,882)

(2,960)

Intangible assets

(126,446)

(115,196)

Lease right-of-use assets

(24,660)

(22,948)

Investment in foreign subsidiary

(4,691)

Total deferred tax liabilities

(161,135)

(146,657)

Total net deferred tax liability

$ (71,288)

$ (46,808)

[1]	The presentation of the December 31, 2020 deferred tax liability attributable to the U.K. divestiture has been adjusted to reflect the final outcome of the sale.

Income Taxes - Unrecognized Income Tax Benefits Net of Federal Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Balance at January 1	$ 2,060	$ 2,441
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities	$ (2,060)	(381)
Balance at December 31		$ 2,060

Derivatives - Additional Information (Detail)	1 Months Ended
Derivatives - Additional Information (Detail)	Aug. 31, 2019 USD ($)	Aug. 31, 2019 GBP (£)	Dec. 31, 2020 USD ($)	Aug. 31, 2019 GBP (£)
Derivative [Line Items]
Cross currency swap liabilities			$ 84,600,000
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000.0			£ 538,100,000
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 25,400,000

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt		$ 3,625
Carrying Amount [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt		3,625
Derivative instrument liabilities		84,584
Carrying Amount [Member] \| New Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Revolving Facility	$ 584,418
Carrying Amount [Member] \| Prior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Revolving Facility		1,175,437
Carrying Amount [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		646,344
Carrying Amount [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		385,636
Carrying Amount [Member] \| 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	443,894	443,139
Carrying Amount [Member] \| 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	468,907	468,245
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt		3,625
Derivative instrument liabilities		84,584
Fair Value [Member] \| New Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
New Credit Facility	584,418
Fair Value [Member] \| Prior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
New Credit Facility		1,175,437
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		647,960
Fair Value [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes		393,850
Fair Value [Member] \| 5.500% Senior Notes due 2028 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	466,577	475,931
Fair Value [Member] \| 5.000% Senior Notes due 2029 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 481,802	$ 499,852

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2021	Dec. 31, 2020	Oct. 14, 2020	Jun. 24, 2020	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%				5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%			6.50%
5.500% Senior Notes due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
5.000% Senior Notes due 2029 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.00%	5.00%	5.00%

Commitments and Contingencies - Additional Information (Detail) $ in Millions	3 Months Ended
	Jun. 30, 2020 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Transaction-related expenses	$ 4.0

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan [Member] \| 401(k) [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution expense	$ 2.8	$ 3.8	$ 4.1

Financial Information Combined Wholly-Owned Subsidiaries - Additional Information (Detail)	Dec. 31, 2021	Dec. 31, 2020	Oct. 14, 2020	Jun. 24, 2020	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015
5.500% Senior Notes due 2028 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.50%	5.50%		5.50%
5.000% Senior Notes due 2029 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.00%	5.00%	5.00%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%	5.625%				5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%			6.50%

Financial Information Combined Wholly-Owned Subsidiaries - Summarized Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Condensed Financial Statements, Captions [Line Items]
Current assets	$ 495,031	$ 2,523,395
Property and equipment, net	1,771,159	1,622,896
Goodwill	2,199,937	2,105,264	$ 2,085,104
Current liabilities	404,861	1,308,185
Long-term debt	1,478,626	2,968,948
Redeemable noncontrolling interests	65,388	55,315	33,151
Total equity	2,517,489	1,899,456	$ 2,505,381	$ 2,333,307
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Current assets	422,113	654,735
Property and equipment, net	1,525,569	1,421,875
Goodwill	2,086,978	1,992,305
Total noncurrent assets	3,893,087	3,640,809
Current liabilities	385,044	626,419
Long-term debt	1,460,046	2,786,125
Total noncurrent liabilities	1,752,271	3,045,981
Total equity	$ 2,177,885	$ 623,144

Financial Information Combined Wholly-Owned Subsidiaries - Summarized Statements of Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Financial Statements, Captions [Line Items]
Revenue	$ 2,314,394	$ 2,089,929	$ 2,008,381
Income from continuing operations before income taxes	275,760	183,797	78,395
Net income	195,562	(669,199)	110,122
Net income attributable to Acadia Healthcare Company, Inc.	190,635	$ (672,132)	$ 108,923
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue	2,132,637
Income from continuing operations before income taxes	246,473
Net income	184,785
Net income attributable to Acadia Healthcare Company, Inc.	$ 184,785

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794